Journal Article
. 2016 Oct; 17(11):1497-1508.
doi: 10.1016/S1470-2045(16)30498-3.

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Corey J Langer 1 Shirish M Gadgeel 2 Hossein Borghaei 3 Vassiliki A Papadimitrakopoulou 4 Amita Patnaik 5 Steven F Powell 6 Ryan D Gentzler 7 Renato G Martins 8 James P Stevenson 9 Shadia I Jalal 10 Amit Panwalkar 11 James Chih-Hsin Yang 12 Matthew Gubens 13 Lecia V Sequist 14 Mark M Awad 15 Joseph Fiore 16 Yang Ge 16 Harry Raftopoulos 16 Leena Gandhi 17 KEYNOTE-021 investigators  
Affiliations
  • PMID: 27745820
  •     24 References
  •     588 citations

Abstract

Background: Limited evidence exists to show that adding a third agent to platinum-doublet chemotherapy improves efficacy in the first-line advanced non-small-cell lung cancer (NSCLC) setting. The anti-PD-1 antibody pembrolizumab has shown efficacy as monotherapy in patients with advanced NSCLC and has a non-overlapping toxicity profile with chemotherapy. We assessed whether the addition of pembrolizumab to platinum-doublet chemotherapy improves efficacy in patients with advanced non-squamous NSCLC.

Methods: In this randomised, open-label, phase 2 cohort of a multicohort study (KEYNOTE-021), patients were enrolled at 26 medical centres in the USA and Taiwan. Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1) in blocks of four stratified by PD-L1 tumour proportion score (<1% vs ≥1%) using an interactive voice-response system to 4 cycles of pembrolizumab 200 mg plus carboplatin area under curve 5 mg/mL per min and pemetrexed 500 mg/m2 every 3 weeks followed by pembrolizumab for 24 months and indefinite pemetrexed maintenance therapy or to 4 cycles of carboplatin and pemetrexed alone followed by indefinite pemetrexed maintenance therapy. The primary endpoint was the proportion of patients who achieved an objective response, defined as the percentage of patients with radiologically confirmed complete or partial response according to Response Evaluation Criteria in Solid Tumors version 1.1 assessed by masked, independent central review, in the intention-to-treat population, defined as all patients who were allocated to study treatment. Significance threshold was p<0·025 (one sided). Safety was assessed in the as-treated population, defined as all patients who received at least one dose of the assigned study treatment. This trial, which is closed for enrolment but continuing for follow-up, is registered with ClinicalTrials.gov, number NCT02039674.

Findings: Between Nov 25, 2014, and Jan 25, 2016, 123 patients were enrolled; 60 were randomly assigned to the pembrolizumab plus chemotherapy group and 63 to the chemotherapy alone group. 33 (55%; 95% CI 42-68) of 60 patients in the pembrolizumab plus chemotherapy group achieved an objective response compared with 18 (29%; 18-41) of 63 patients in the chemotherapy alone group (estimated treatment difference 26% [95% CI 9-42%]; p=0·0016). The incidence of grade 3 or worse treatment-related adverse events was similar between groups (23 [39%] of 59 patients in the pembrolizumab plus chemotherapy group and 16 [26%] of 62 in the chemotherapy alone group). The most common grade 3 or worse treatment-related adverse events in the pembrolizumab plus chemotherapy group were anaemia (seven [12%] of 59) and decreased neutrophil count (three [5%]); an additional six events each occurred in two (3%) for acute kidney injury, decreased lymphocyte count, fatigue, neutropenia, and sepsis, and thrombocytopenia. In the chemotherapy alone group, the most common grade 3 or worse events were anaemia (nine [15%] of 62) and decreased neutrophil count, pancytopenia, and thrombocytopenia (two [3%] each). One (2%) of 59 patients in the pembrolizumab plus chemotherapy group experienced treatment-related death because of sepsis compared with two (3%) of 62 patients in the chemotherapy group: one because of sepsis and one because of pancytopenia.

Interpretation: Combination of pembrolizumab, carboplatin, and pemetrexed could be an effective and tolerable first-line treatment option for patients with advanced non-squamous NSCLC. This finding is being further explored in an ongoing international, randomised, double-blind, phase 3 study.

Funding: Merck & Co.

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.
Charlotte Roach, Nancy Zhang, +7 authors, Karina Kulangara.
Appl Immunohistochem Mol Morphol, 2016 Jun 23; 24(6). PMID: 27333219    Free PMC article.
Highly Cited.
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.
M Chatterjee, D C Turner, +20 authors, Ø Fløtten.
Ann Oncol, 2016 Apr 28; 27(7). PMID: 27117531    Free PMC article.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, +13 authors, J Verweij.
Eur J Cancer, 2008 Dec 23; 45(2). PMID: 19097774
Highly Cited.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, +16 authors, Edward B Garon.
Lancet, 2015 Dec 30; 387(10027). PMID: 26712084
Highly Cited.
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Alan Sandler, Robert Gray, +5 authors, David H Johnson.
N Engl J Med, 2006 Dec 15; 355(24). PMID: 17167137
Highly Cited.
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Scott Gettinger, Naiyer A Rizvi, +13 authors, Matthew D Hellmann.
J Clin Oncol, 2016 Jun 30; 34(25). PMID: 27354485    Free PMC article.
Highly Cited.
Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
Panpan Zhang, Yuanyuan Ma, +10 authors, Yue Yang.
Cancer Sci, 2016 Sep 02; 107(11). PMID: 27581532    Free PMC article.
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.
Laurence Zitvogel, Lorenzo Galluzzi, Mark J Smyth, Guido Kroemer.
Immunity, 2013 Jul 31; 39(1). PMID: 23890065
Highly Cited. Review.
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Naiyer A Rizvi, Matthew D Hellmann, +13 authors, Scott Antonia.
J Clin Oncol, 2016 Jun 30; 34(25). PMID: 27354481    Free PMC article.
Highly Cited.
PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
Ralph G Zinner, Coleman K Obasaju, +16 authors, Helen J Ross.
J Thorac Oncol, 2014 Nov 06; 10(1). PMID: 25371077    Free PMC article.
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Scott N Gettinger, Leora Horn, +26 authors, Julie R Brahmer.
J Clin Oncol, 2015 Apr 22; 33(18). PMID: 25897158    Free PMC article.
Highly Cited.
Pembrolizumab for the treatment of non-small-cell lung cancer.
Edward B Garon, Naiyer A Rizvi, +25 authors, KEYNOTE-001 Investigators.
N Engl J Med, 2015 Apr 22; 372(21). PMID: 25891174
Highly Cited.
Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk.
C P Farrington, G Manning.
Stat Med, 1990 Dec 01; 9(12). PMID: 2281232
Highly Cited.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, +25 authors, Julie R Brahmer.
N Engl J Med, 2015 Sep 29; 373(17). PMID: 26412456    Free PMC article.
Highly Cited.
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
L Apetoh, S Ladoire, G Coukos, F Ghiringhelli.
Ann Oncol, 2015 Apr 30; 26(9). PMID: 25922066
Highly Cited. Review.
A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Wolfgang H W Schuette, Andreas Gröschel, +8 authors, Martin Reck.
Clin Lung Cancer, 2013 Jan 22; 14(3). PMID: 23332288
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Louis Fehrenbacher, Alexander Spira, +16 authors, POPLAR Study Group.
Lancet, 2016 Mar 14; 387(10030). PMID: 26970723
Highly Cited.
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.
Lorenzo Galluzzi, Aitziber Buqué, +2 authors, Guido Kroemer.
Cancer Cell, 2015 Dec 19; 28(6). PMID: 26678337
Highly Cited. Review.
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).
M Reck, J von Pawel, +9 authors, BO17704 Study Group.
Ann Oncol, 2010 Feb 13; 21(9). PMID: 20150572    Free PMC article.
Highly Cited.
The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials.
P Wheatley-Price, F Blackhall, +11 authors, F A Shepherd.
Ann Oncol, 2010 Mar 25; 21(10). PMID: 20332134
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, +22 authors, David R Spigel.
N Engl J Med, 2015 Jun 02; 373(2). PMID: 26028407    Free PMC article.
Highly Cited.
Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.
Jin Peng, Junzo Hamanishi, +9 authors, Masaki Mandai.
Cancer Res, 2015 Nov 18; 75(23). PMID: 26573793
Highly Cited.
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Luis Paz-Ares, Filippo de Marinis, +14 authors, Cesare Gridelli.
Lancet Oncol, 2012 Feb 22; 13(3). PMID: 22341744
Highly Cited.
Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab.
H A Wakelee, S E Dahlberg, +7 authors, Eastern Cooperative Oncology Group.
Lung Cancer, 2012 Jan 24; 76(3). PMID: 22266041    Free PMC article.
Lung cancer: Anti-PD-1 therapy in the frontline.
David Killock.
Nat Rev Clin Oncol, 2016 Nov 03; 13(12). PMID: 27779237
Annual Congress of the European Society for Medical Oncology (ESMO): Copenhagen, Denmark; 7-11 October 2016.
Martin Chopra.
Target Oncol, 2016 Nov 05; 11(6). PMID: 27812901
Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.
Samuel A Funt, Jonathan E Rosenberg.
Nat Rev Clin Oncol, 2016 Nov 23; 14(4). PMID: 27874062    Free PMC article.
Review.
Immuno-Oncology: The Third Paradigm in Early Drug Development.
Juan Martin-Liberal, Cinta Hierro, Maria Ochoa de Olza, Jordi Rodon.
Target Oncol, 2016 Dec 21; 12(2). PMID: 27995439
Biomarkers come of age: PD1 in the frontline and cell cycle therapy swells the ranks of personalised therapy in the European Society of Medical Oncology (ESMO) congress, Copenhagen, 7-10 October 2016.
Will Davies.
Ecancermedicalscience, 2017 Jan 21; 10. PMID: 28105074    Free PMC article.
Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer.
Xiaoming Liu, William C Cho.
Clin Transl Med, 2017 Jan 22; 6(1). PMID: 28108884    Free PMC article.
Targeting ALK: Precision Medicine Takes on Drug Resistance.
Jessica J Lin, Gregory J Riely, Alice T Shaw.
Cancer Discov, 2017 Jan 27; 7(2). PMID: 28122866    Free PMC article.
Highly Cited. Review.
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.
M-S Tsao, G Le Teuff, +11 authors, E Brambilla.
Ann Oncol, 2017 Feb 01; 28(4). PMID: 28137741    Free PMC article.
Highly Cited.
Preface on "Emerging treatment options for brain metastases from non-small cell lung cancer".
Giulio Metro, Rita Chiari.
Transl Lung Cancer Res, 2017 Feb 06; 5(6). PMID: 28149751    Free PMC article.
Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer.
Chiara Lazzari, Alessandra Bulotta, +5 authors, Vanesa Gregorc.
Front Med (Lausanne), 2017 Feb 09; 4. PMID: 28168189    Free PMC article.
Review.
[Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer].
Zhansheng Jiang, Zhanyu Pan, Xiubao Ren.
Zhongguo Fei Ai Za Zhi, 2017 Feb 24; 20(2). PMID: 28228226    Free PMC article.
Review.
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.
Guillermo De Velasco, Youjin Je, +8 authors, Toni K Choueiri.
Cancer Immunol Res, 2017 Mar 02; 5(4). PMID: 28246107    Free PMC article.
Highly Cited.
Standard of care in immunotherapy trials: Challenges and considerations.
Gareth Rivalland, Andrew M Scott, Thomas John.
Hum Vaccin Immunother, 2017 Mar 08; 13(9). PMID: 28267397    Free PMC article.
Review.
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
Jordi Remon, Benjamin Besse, Jean-Charles Soria.
BMC Med, 2017 Mar 14; 15(1). PMID: 28285592    Free PMC article.
Review.
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Carminia Maria Della Corte, Umberto Malapelle, +8 authors, Floriana Morgillo.
Oncotarget, 2017 Apr 19; 8(14). PMID: 28416737    Free PMC article.
Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer.
Marco A J Iafolla, Rosalyn A Juergens.
Front Oncol, 2017 Apr 22; 7. PMID: 28428947    Free PMC article.
Review.
Emerging therapies for breast cancer.
Xichun Hu, Wei Huang, Minhao Fan.
J Hematol Oncol, 2017 Apr 30; 10(1). PMID: 28454587    Free PMC article.
Review.
AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future.
Anil Vachani, Lecia V Sequist, Avrum Spira.
Am J Respir Crit Care Med, 2017 May 02; 195(9). PMID: 28459327    Free PMC article.
Review.
The KEY to the end of chemotherapy in non-small cell lung cancer?
Yiqing Huang, Ross A Soo.
Ann Transl Med, 2017 May 10; 5(7). PMID: 28480202    Free PMC article.
Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?
Chethan Ramamurthy, James L Godwin, Hossein Borghaei.
Curr Treat Options Oncol, 2017 May 24; 18(6). PMID: 28534248
Review.
Metabolic rewiring in mutant Kras lung cancer.
Emma M Kerr, Carla P Martins.
FEBS J, 2017 Jun 02; 285(1). PMID: 28570035    Free PMC article.
Review.
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Glen J Weiss, Jordan Waypa, +7 authors, Vivek Khemka.
Br J Cancer, 2017 Jun 08; 117(1). PMID: 28588322    Free PMC article.
Autophagic Mechanism in Anti-Cancer Immunity: Its Pros and Cons for Cancer Therapy.
Ying-Ying Li, Lynn G Feun, +6 authors, Niramol Savaraj.
Int J Mol Sci, 2017 Jun 21; 18(6). PMID: 28629173    Free PMC article.
Review.
[Prospect and Current Situation of Immune Checkpoint Inhibitors 
in First-line Treatment in Advanced Non-small Cell Lung Cancer Patients].
Haiyang Wang, Xiaoqing Yu, Yun Fan.
Zhongguo Fei Ai Za Zhi, 2017 Jun 24; 20(6). PMID: 28641702    Free PMC article.
Review.
Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope.
Jonathan M Lehman, Mary E Gwin, Pierre P Massion.
Curr Oncol Rep, 2017 Jun 24; 19(7). PMID: 28643173
Review.
Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome.
Mizuki Nishino, Suzanne E Dahlberg, +5 authors, Mark M Awad.
Clin Cancer Res, 2017 Jul 07; 23(19). PMID: 28679767    Free PMC article.
Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.
Cesare Gridelli, Andrea Ardizzoni, +5 authors, Filippo De Marinis.
Transl Lung Cancer Res, 2017 Jul 18; 6(3). PMID: 28713682    Free PMC article.
Review.
Pembrolizumab-Induced Pancytopenia: A Case Report.
Dinesh Atwal, Krishna P Joshi, Rahul Ravilla, Fade Mahmoud.
Perm J, 2017 Jul 27; 21. PMID: 28746020    Free PMC article.
Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults.
Rawad Elias, Joshua Morales, Carolyn Presley.
Curr Oncol Rep, 2017 Jul 30; 19(9). PMID: 28755314
Review.
PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence.
Phu N Tran, Sarmen Sarkissian, Joseph Chao, Samuel J Klempner.
Gastrointest Cancer, 2017 Aug 02; 7. PMID: 28757801    Free PMC article.
New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
Nagashree Seetharamu, Isabel R Preeshagul, Kevin M Sullivan.
Lung Cancer (Auckl), 2017 Aug 02; 8. PMID: 28761384    Free PMC article.
Review.
Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found….
Satheesh Thungappa, Jose Ferri, +3 authors, Christian Rolfo.
ESMO Open, 2017 Aug 02; 2(1). PMID: 28761734    Free PMC article.
ESMO Copenhagen 2016: a lung cancer 'grand cru'.
Jean-Yves Douillard.
ESMO Open, 2017 Aug 02; 2(2). PMID: 28761753    Free PMC article.
Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.
Dylan J Martini, Aly-Khan A Lalani, +5 authors, Toni K Choueiri.
J Immunother Cancer, 2017 Aug 16; 5(1). PMID: 28807048    Free PMC article.
Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.
Roberto Chalela, Víctor Curull, +3 authors, Joaquim Gea.
J Thorac Dis, 2017 Aug 26; 9(7). PMID: 28840016    Free PMC article.
Review.
Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Carmelo Tibaldi, Alice Lunghi, Editta Baldini.
World J Clin Oncol, 2017 Aug 30; 8(4). PMID: 28848698    Free PMC article.
Review.
Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies.
Lillian L Siu, S Percy Ivy, +3 authors, Gary L Rosner.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864723    Free PMC article.
From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.
Daphne Day, Arta M Monjazeb, +4 authors, Marcus O Butler.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864726    Free PMC article.
Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events.
Marianne Davies, Emily A Duffield.
Immunotargets Ther, 2017 Sep 13; 6. PMID: 28894725    Free PMC article.
Review.
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
Alastair Greystoke, Nicola Steele, +12 authors, Emma Dean.
Br J Cancer, 2017 Sep 28; 117(7). PMID: 28950288    Free PMC article.
Genetic Characterization of Brain Metastases in the Era of Targeted Therapy.
Catherine H Han, Priscilla K Brastianos.
Front Oncol, 2017 Oct 11; 7. PMID: 28993799    Free PMC article.
Review.
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016.
Paolo A Ascierto, Bruno Daniele, +5 authors, Sandro Pignata.
J Transl Med, 2017 Oct 13; 15(1). PMID: 29020960    Free PMC article.
PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed.
Pei Zhang, Zhang Bao, +7 authors, Jianying Zhou.
Oncotarget, 2017 Oct 17; 8(39). PMID: 29029512    Free PMC article.
PD-L1 as a biomarker in NSCLC: challenges and future directions.
Matthen Mathew, Rachael A Safyan, Catherine A Shu.
Ann Transl Med, 2017 Oct 24; 5(18). PMID: 29057235    Free PMC article.
[A Reflection of the New Wave of Immunotherapy on the Clinical Study of 
Chinese Lung Cancer Immunotherapy].
Jingjing Liu, Shuang Zhang, Shuang Li, Ying Cheng.
Zhongguo Fei Ai Za Zhi, 2017 Oct 25; 20(10). PMID: 29061217    Free PMC article.
Review.
Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy.
Daiki Ogawara, Hiroshi Soda, +4 authors, Hiroshi Mukae.
Thorac Cancer, 2017 Oct 25; 9(1). PMID: 29063735    Free PMC article.
Advances in lung cancer.
Jose M Pacheco, Anastasios Dimou, Paul A Bunn.
Oncotarget, 2017 Nov 08; 8(45). PMID: 29108218    Free PMC article.
Saudi lung cancer management guidelines 2017: Improving lung cancer care in Saudi region.
Christian Rolfo, Christoph C Zielinski.
Ann Thorac Med, 2017 Nov 10; 12(4). PMID: 29118854    Free PMC article.
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.
Glen J Weiss, Lisa Blaydorn, +4 authors, Vivek Khemka.
Invest New Drugs, 2017 Nov 10; 36(1). PMID: 29119276
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer.
Katerina Ancevski Hunter, Mark A Socinski, Liza C Villaruz.
Mol Diagn Ther, 2017 Nov 10; 22(1). PMID: 29119407    Free PMC article.
Review.
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.
Jessica S Brown, Raghav Sundar, Juanita Lopez.
Br J Cancer, 2017 Nov 11; 118(3). PMID: 29123260    Free PMC article.
Highly Cited. Review.
Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma.
Shuyu D Li, Annia Martial, Alexa B Schrock, Jane J Liu.
Exp Hematol Oncol, 2017 Nov 17; 6. PMID: 29142786    Free PMC article.
Suppression from beyond the grave.
Yosuke Togashi, Hiroyoshi Nishikawa.
Nat Immunol, 2017 Nov 17; 18(12). PMID: 29144496
Trial watch: Immune checkpoint blockers for cancer therapy.
Claire Vanpouille-Box, Claire Lhuillier, +10 authors, Lorenzo Galluzzi.
Oncoimmunology, 2017 Nov 18; 6(11). PMID: 29147629    Free PMC article.
Highly Cited. Review.
Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.
Misako Nagasaka, Shirish M Gadgeel.
Expert Rev Anticancer Ther, 2017 Nov 24; 18(1). PMID: 29168933    Free PMC article.
Review.
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells.
Hiro Sato, Atsuko Niimi, +14 authors, Atsushi Shibata.
Nat Commun, 2017 Nov 25; 8(1). PMID: 29170499    Free PMC article.
Highly Cited.
Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma.
Takeharu Ono, Koichi Azuma, +7 authors, Umeno Hirohito.
Oncotarget, 2017 Dec 02; 8(54). PMID: 29190949    Free PMC article.
Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
Jung Han Kim, Hyeong Su Kim, Bum Jun Kim.
Oncotarget, 2017 Dec 02; 8(54). PMID: 29190984    Free PMC article.
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.
Bingshan Liu, Yongping Song, Delong Liu.
J Hematol Oncol, 2017 Dec 03; 10(1). PMID: 29195503    Free PMC article.
Highly Cited. Review.
Excellent response to chemotherapy post immunotherapy.
Ashish D Dwary, Samip Master, +8 authors, Kavitha Beedupalli.
Oncotarget, 2017 Dec 07; 8(53). PMID: 29207685    Free PMC article.
Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets.
Pedro Nazareth Aguiar, Ramon Andrade De Mello, +4 authors, Gilberto de Lima Lopes.
ESMO Open, 2017 Dec 07; 2(3). PMID: 29209522    Free PMC article.
Review.
Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.
Xiuning Le, Deepa Rangachari, Daniel B Costa.
J Thorac Dis, 2017 Dec 10; 9(9). PMID: 29221246    Free PMC article.
The Role of Checkpoint Inhibition in Non-Small Cell Lung Cancer.
Jonathan Lu, Robert A Ramirez.
Ochsner J, 2017 Dec 13; 17(4). PMID: 29230122    Free PMC article.
Review.
Histologic Grade Is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma.
Michelle Levy, Liisa Lyon, +4 authors, Minggui Pan.
Med Sci (Basel), 2017 Dec 14; 5(4). PMID: 29232915    Free PMC article.
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Andrea Botticelli, Concetta Elisa Onesti, +15 authors, Paolo Marchetti.
Oncotarget, 2017 Dec 17; 8(59). PMID: 29245905    Free PMC article.
ASCO update: lung cancer.
Gudrun Absenger, Jasmin Terzic, Angelika Bezan.
Memo, 2017 Dec 19; 10(4). PMID: 29250201    Free PMC article.
Review.
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Zijun Y Xu-Monette, Mingzhi Zhang, Jianyong Li, Ken H Young.
Front Immunol, 2017 Dec 20; 8. PMID: 29255458    Free PMC article.
Highly Cited. Review.
A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer.
Rachel E Sanborn, Helen J Ross, +12 authors, Bernard A Fox.
J Immunother Cancer, 2017 Dec 21; 5(1). PMID: 29258618    Free PMC article.
KEYNOTE-010: flash of a supernova (immune-checkpoint inhibitors) in second-line non-small cell lung cancer.
Hidehito Horinouchi.
J Thorac Dis, 2017 Dec 23; 9(11). PMID: 29268467    Free PMC article.
Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura.
James T Boothe, G Thomas Budd, Matthew B Smolkin, Patrick C Ma.
Case Rep Oncol, 2017 Dec 28; 10(3). PMID: 29279705    Free PMC article.
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.
Bert H O'Neil, John M Wallmark, +14 authors, Sae-Won Han.
PLoS One, 2017 Dec 29; 12(12). PMID: 29284010    Free PMC article.
Highly Cited.
Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care.
Omer Ben-Aharon, Racheli Magnezi, Moshe Leshno, Daniel A Goldstein.
JAMA Oncol, 2017 Dec 30; 4(3). PMID: 29285547    Free PMC article.
Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis.
Yang-Bo Hu, Qun Zhang, +6 authors, written on behalf of the AME Academic Lung Cancer Cooperation Group.
Transl Lung Cancer Res, 2018 Jan 05; 6(Suppl 1). PMID: 29299404    Free PMC article.
Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer.
Hao Xie, Alex A Adjei.
Transl Lung Cancer Res, 2018 Jan 05; 6(Suppl 1). PMID: 29299408    Free PMC article.
Inhibitors of the PD-1 Pathway in Tumor Therapy.
Martin W LaFleur, Yuki Muroyama, Charles G Drake, Arlene H Sharpe.
J Immunol, 2018 Jan 10; 200(2). PMID: 29311378    Free PMC article.
Review.
Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Chi Young Jung, Scott J Antonia.
Tuberc Respir Dis (Seoul), 2018 Jan 15; 81(1). PMID: 29332322    Free PMC article.
Review.
Remarkable response with pembrolizumab plus albumin-bound paclitaxel in 2 cases of HER2-positive metastatic breast cancer who have failed to multi-anti-HER2 targeted therapy.
Bian Li, Wang Tao, +4 authors, Jiang Ze-Fei.
Cancer Biol Ther, 2018 Jan 16; 19(4). PMID: 29333945    Free PMC article.
Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.
Hua Zheng, Masha Zeltsman, +3 authors, Prasad S Adusumilli.
Immunotherapy, 2018 Jan 18; 9(11). PMID: 29338609    Free PMC article.
Review.
Cancer vaccine: learning lessons from immune checkpoint inhibitors.
ZhenLong Ye, Qiming Qian, HuaJun Jin, QiJun Qian.
J Cancer, 2018 Jan 19; 9(2). PMID: 29344272    Free PMC article.
Review.
TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma.
Charlotte Leduc, Julien Adam, +15 authors, Sophie Postel-Vinay.
ESMO Open, 2018 Jan 19; 3(1). PMID: 29344407    Free PMC article.
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.
Jun Gong, Alexander Chehrazi-Raffle, Srikanth Reddi, Ravi Salgia.
J Immunother Cancer, 2018 Jan 24; 6(1). PMID: 29357948    Free PMC article.
Highly Cited. Review.
PD-1/PD-L1 Axis in Lung Cancer.
Fernando C Santini, Matthew D Hellmann.
Cancer J, 2018 Jan 24; 24(1). PMID: 29360723    Free PMC article.
Review.
The biology and management of non-small cell lung cancer.
Roy S Herbst, Daniel Morgensztern, Chris Boshoff.
Nature, 2018 Jan 25; 553(7689). PMID: 29364287
Highly Cited. Review.
Immune gene expression and response to chemotherapy in advanced breast cancer.
Theodoros Foukakis, John Lövrot, +14 authors, Thomas Hatschek.
Br J Cancer, 2018 Jan 26; 118(4). PMID: 29370583    Free PMC article.
The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
Amy L Cummings, Edward B Garon.
Cancer Biol Med, 2018 Jan 27; 14(4). PMID: 29372100    Free PMC article.
Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC).
Irene Moya-Horno, Santiago Viteri, Niki Karachaliou, Rafael Rosell.
Ther Adv Med Oncol, 2018 Feb 01; 10. PMID: 29383034    Free PMC article.
Highly Cited. Review.
Role of immune-checkpoint inhibitors in lung cancer.
Prantesh Jain, Chhavi Jain, Vamsidhar Velcheti.
Ther Adv Respir Dis, 2018 Feb 02; 12. PMID: 29385894    Free PMC article.
Review.
Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.
Izak Faiena, Amy L Cummings, +3 authors, Alexandra Drakaki.
Drug Des Devel Ther, 2018 Feb 09; 12. PMID: 29416316    Free PMC article.
Review.
Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer.
Shalin Shah, Kevin Wood, +8 authors, Jason J Luke.
Oncotarget, 2018 Feb 13; 9(4). PMID: 29435109    Free PMC article.
Immune Checkpoint Blockade: The New Frontier in Cancer Treatment.
Jeffrey M Clarke, Daniel J George, Stacey Lisi, April K S Salama.
Target Oncol, 2018 Feb 15; 13(1). PMID: 29441437
The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective.
Helmy M Guirgis.
J Immunother Cancer, 2018 Feb 22; 6(1). PMID: 29463302    Free PMC article.
Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.
Georgia Ritchie, Harry Gasper, +4 authors, Chee Khoon Lee.
JAMA Oncol, 2018 Feb 23; 4(4). PMID: 29470579    Free PMC article.
Systematic Review.
The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies.
Emily Z Keung, Esosa U Ukponmwan, Alexandria P Cogdill, Jennifer A Wargo.
Ann Surg Oncol, 2018 Mar 04; 25(7). PMID: 29500764    Free PMC article.
Phase I study of concurrent and consolidation cisplatin and docetaxel chemotherapy with thoracic radiotherapy in non-small cell lung cancer.
T W Zhang, G B Rodrigues, +9 authors, M D Vincent.
Curr Oncol, 2018 Mar 07; 25(1). PMID: 29507480    Free PMC article.
Pulmonary Sarcoidosis Activation following Neoadjuvant Pembrolizumab plus Chemotherapy Combination Therapy in a Patient with Non-Small Cell Lung Cancer: A Case Report.
Ghina Fakhri, Reem Akel, +2 authors, Arafat Tfayli.
Case Rep Oncol, 2018 Mar 09; 10(3). PMID: 29515398    Free PMC article.
A proteomic landscape of diffuse-type gastric cancer.
Sai Ge, Xia Xia, +36 authors, Jun Qin.
Nat Commun, 2018 Mar 10; 9(1). PMID: 29520031    Free PMC article.
Highly Cited.
[Research Advances of Pan-negative Type of Non-small Cell Lung Cancer].
Li Sun, Zhicheng Xiong, Chengbo Han.
Zhongguo Fei Ai Za Zhi, 2018 Mar 13; 21(2). PMID: 29526181    Free PMC article.
Review.
Putting the brakes on CTLA-4 inhibition in lung cancer?
Meghan J Mooradian, Justin F Gainor.
Transl Lung Cancer Res, 2018 Mar 14; 7(Suppl 1). PMID: 29531902    Free PMC article.
Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.
Shrujal Baxi, Annie Yang, +4 authors, Deborah Korenstein.
BMJ, 2018 Mar 16; 360. PMID: 29540345    Free PMC article.
Highly Cited. Systematic Review.
Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis.
Hao Hu, Qian Zhu, +3 authors, Chang Ying Guo.
Oncotarget, 2018 Mar 17; 9(14). PMID: 29545941    Free PMC article.
Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
Yiming Wang, Rena Ma, +2 authors, Li Zhang.
Front Immunol, 2018 Mar 21; 9. PMID: 29556232    Free PMC article.
Review.
Current Strategies to Enhance Anti-Tumour Immunity.
Katherine W Cook, Lindy G Durrant, Victoria A Brentville.
Biomedicines, 2018 Mar 24; 6(2). PMID: 29570634    Free PMC article.
Review.
Immunotherapy in treatment naïve advanced non-small cell lung cancer.
Vinicius Ernani, Apar Kishor Ganti.
J Thorac Dis, 2018 Mar 30; 10(Suppl 3). PMID: 29593887    Free PMC article.
Review.
Immunotherapy in previously treated non-small cell lung cancer (NSCLC).
Ticiana A Leal, Suresh S Ramalingam.
J Thorac Dis, 2018 Mar 30; 10(Suppl 3). PMID: 29593888    Free PMC article.
Review.
Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer.
Justin Yeh, Kristen A Marrone, Patrick M Forde.
J Thorac Dis, 2018 Mar 30; 10(Suppl 3). PMID: 29593890    Free PMC article.
Review.
Square peg, round hole? Programmed death-1 inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer.
Justin F Gainor.
J Thorac Dis, 2018 Mar 31; 10(1). PMID: 29600014    Free PMC article.
Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711).
Ajeet Gajra, Tyler J Zemla, +12 authors, Jennifer G Le-Rademacher.
J Thorac Oncol, 2018 Apr 03; 13(7). PMID: 29608967    Free PMC article.
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
John M Wrangle, Vamsidhar Velcheti, +26 authors, Mark P Rubinstein.
Lancet Oncol, 2018 Apr 10; 19(5). PMID: 29628312    Free PMC article.
Highly Cited.
Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials.
C Bryce Johnson, Shwe Y Win.
Oncoimmunology, 2018 Apr 11; 7(4). PMID: 29632719    Free PMC article.
STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer.
Ilaria Attili, Niki Karachaliou, +6 authors, Rafael Rosell.
Ther Adv Med Oncol, 2018 Apr 11; 10. PMID: 29636826    Free PMC article.
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.
Amila Suraweera, Kenneth J O'Byrne, Derek J Richard.
Front Oncol, 2018 Apr 14; 8. PMID: 29651407    Free PMC article.
Highly Cited. Review.
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
Chiara Lazzari, Niki Karachaliou, +7 authors, Vanesa Gregorc.
Ther Adv Med Oncol, 2018 Apr 18; 10. PMID: 29662546    Free PMC article.
Highly Cited. Review.
Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice.
Efimia Boutsikou, Kalliopi Domvri, +3 authors, Theodoros Kontakiotis.
Ther Adv Med Oncol, 2018 Apr 18; 10. PMID: 29662549    Free PMC article.
CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial.
Dean A Fennell, Emma Kirkpatrick, +13 authors, Gareth Griffiths.
Trials, 2018 Apr 20; 19(1). PMID: 29669604    Free PMC article.
CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.
Yiyi Yan, Siyu Cao, +12 authors, Haidong Dong.
JCI Insight, 2018 Apr 20; 3(8). PMID: 29669928    Free PMC article.
Efficacy of pemetrexed-based regimens in advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review.
BaoHui Han, LuLu Yang, Xin Wang, LuanDi Yao.
Onco Targets Ther, 2018 Apr 27; 11. PMID: 29695919    Free PMC article.
Review.
Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC).
Silvia Vecchiarelli, Francesco Passiglia, +12 authors, Federico Cappuzzo.
Oncotarget, 2018 May 01; 9(25). PMID: 29707129    Free PMC article.
New data: new options for front-line therapy in NSCLC?
Niels Reinmuth.
ESMO Open, 2018 May 02; 3(3). PMID: 29713500    Free PMC article.
Checkpoint Inhibitors in the Treatment of Breast Cancer.
Tomas G Lyons, Maura N Dickler, Elizabeth E Comen.
Curr Oncol Rep, 2018 May 02; 20(7). PMID: 29713831
Review.
Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism.
Jaafar Jaafar, Eugenio Fernandez, Heba Alwan, Jacques Philippe.
Endocr Connect, 2018 May 10; 7(5). PMID: 29739808    Free PMC article.
Review.
Combination Immunotherapy in Non-small Cell Lung Cancer.
Melina E Marmarelis, Charu Aggarwal.
Curr Oncol Rep, 2018 May 10; 20(7). PMID: 29740718
Review.
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
Hossein Maymani, Kenneth Hess, +14 authors, Vivek Subbiah.
Lung Cancer, 2018 May 12; 120. PMID: 29748008    Free PMC article.
Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature.
Shagufta Shaheen, Hamid Mirshahidi, Gayathri Nagaraj, Chung-Tsen Hsueh.
Exp Hematol Oncol, 2018 May 16; 7. PMID: 29761026    Free PMC article.
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
Ioannis Zerdes, Alexios Matikas, +2 authors, Theodoros Foukakis.
Oncogene, 2018 May 17; 37(34). PMID: 29765155    Free PMC article.
Highly Cited. Review.
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis, Michael E Goldberg, +66 authors, John V Heymach.
Cancer Discov, 2018 May 19; 8(7). PMID: 29773717    Free PMC article.
Highly Cited.
Quality of life for non-small cell lung cancer patients in the age of immunotherapy.
Robert A Ramirez, Jonathan Lu, Katharine E H Thomas.
Transl Lung Cancer Res, 2018 May 22; 7(Suppl 2). PMID: 29782567    Free PMC article.
Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.
Nicholas Borcherding, Ryan Kolb, +3 authors, Weizhou Zhang.
J Mol Biol, 2018 May 26; 430(14). PMID: 29800567    Free PMC article.
Review.
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan.
Shu-Yung Lin, Ching-Yao Yang, +13 authors, Chong-Jen Yu.
J Cancer, 2018 May 29; 9(10). PMID: 29805708    Free PMC article.
Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience.
Mohammed Salhab, Yazan Migdady, +5 authors, James Liebmann.
J Immunother Cancer, 2018 May 31; 6(1). PMID: 29843803    Free PMC article.
Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622).
Josephine L Feliciano, Jennifer G Le-Rademacher, +9 authors, Aminah Jatoi.
J Geriatr Oncol, 2018 Jun 01; 9(5). PMID: 29848457    Free PMC article.
Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study.
Takehiro Uemura, Toyoaki Hida.
J Thorac Dis, 2018 Jun 01; 10(Suppl 9). PMID: 29850190    Free PMC article.
The emerging treatment landscape of advanced non-small cell lung cancer.
Panagiota Economopoulou, Giannis Mountzios.
Ann Transl Med, 2018 Jun 05; 6(8). PMID: 29862227    Free PMC article.
Review.
Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau?
Panagiotis Baxevanos, Giannis Mountzios.
Ann Transl Med, 2018 Jun 05; 6(8). PMID: 29862228    Free PMC article.
Review.
Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).
Anna Tsiara, Michalis Liontos, +3 authors, Meletios-Athanasios Dimopoulos.
Ann Transl Med, 2018 Jun 05; 6(8). PMID: 29862233    Free PMC article.
Review.
Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?
Georgios Tsironis, Dimitrios C Ziogas, +4 authors, Meletios-Athanasios Dimopoulos.
Ann Transl Med, 2018 Jun 05; 6(8). PMID: 29862232    Free PMC article.
Review.
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination.
Jun Gong, Thang Q Le, +2 authors, Richard Tuli.
J Immunother Cancer, 2018 Jun 06; 6(1). PMID: 29866197    Free PMC article.
Review.
Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer.
Howard J Lee, Jing Zeng, Ramesh Rengan.
Transl Lung Cancer Res, 2018 Jun 08; 7(2). PMID: 29876317    Free PMC article.
Review.
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
P D Bonomi, D Gandara, +22 authors, N Thatcher.
Ann Oncol, 2018 Jun 16; 29(8). PMID: 29905778    Free PMC article.
Review.
Rapidly changing treatment algorithms for metastatic nonsquamous non-small-cell lung cancer.
B Melosky.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910649    Free PMC article.
Review.
Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.
A Pabani, C A Butts.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910652    Free PMC article.
Review.
Experimental animal study of docetaxel combined with carboplatin in the treatment of retinoblastoma.
Caiping Song, Qiang Zhang.
Oncol Lett, 2018 Jun 22; 16(1). PMID: 29928406    Free PMC article.
30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT).
Filippo de Marinis, Fortunato Ciardiello, +10 authors, Cesare Gridelli.
ESMO Open, 2018 Jun 27; 3(4). PMID: 29942662    Free PMC article.
Review.
Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer.
Jin-Hua Chen, Jia-Lian Yang, +2 authors, Chin-Chuan Hung.
Sci Rep, 2018 Jun 28; 8(1). PMID: 29946182    Free PMC article.
Review.
Immunotherapy in the Asiatic population: any differences from Caucasian population?
Lunxi Peng, Yi-Long Wu.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951300    Free PMC article.
Review.
Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.
Jordi Remon, Laura Mezquita, +2 authors, Noemi Reguart.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951303    Free PMC article.
Review.
A review of guidelines for lung cancer.
Paolo Bironzo, Massimo Di Maio.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951306    Free PMC article.
Review.
Oncogene-addicted non-small cell lung cancer and immunotherapy.
Georgios Tsakonas, Simon Ekman.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951305    Free PMC article.
Review.
Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors.
Meng Qiao, Tao Jiang, Caicun Zhou.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951304    Free PMC article.
Review.
PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy.
Long Jia, Qi Zhang, Rongxin Zhang.
Cancer Biol Med, 2018 Jun 29; 15(2). PMID: 29951336    Free PMC article.
Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective.
D N Ionescu, M R Downes, A Christofides, M S Tsao.
Curr Oncol, 2018 Jul 03; 25(3). PMID: 29962847    Free PMC article.
Review.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
Julie R Brahmer, Ramaswamy Govindan, +18 authors, Roy S Herbst.
J Immunother Cancer, 2018 Jul 18; 6(1). PMID: 30012210    Free PMC article.
A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
Taichi Takashina, Hajime Asahina, +17 authors, Hokkaido Lung Cancer Clinical Study Group.
Int J Clin Oncol, 2018 Jul 22; 23(6). PMID: 30027464
New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab.
Olivier Bylicki, Nicolas Paleiron, Gaëlle Rousseau-Bussac, Christos Chouaïd.
Onco Targets Ther, 2018 Jul 25; 11. PMID: 30038505    Free PMC article.
Review.
Emerging strategies for combination checkpoint modulators in cancer immunotherapy.
Aleksandra Popovic, Elizabeth M Jaffee, Neeha Zaidi.
J Clin Invest, 2018 Aug 02; 128(8). PMID: 30067248    Free PMC article.
Highly Cited. Review.
A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer.
Muhammad Zubair Afzal, Konstantin Dragnev, Keisuke Shirai.
J Thorac Dis, 2018 Aug 03; 10(6). PMID: 30069355    Free PMC article.
BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer.
Dennis O Adeegbe, Shengwu Liu, +18 authors, Kwok-Kin Wong.
Cancer Immunol Res, 2018 Aug 09; 6(10). PMID: 30087114    Free PMC article.
Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects.
Rachel Ryu, Kristina E Ward.
Front Oncol, 2018 Aug 09; 8. PMID: 30087855    Free PMC article.
Review.
Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer).
Jaafar Bennouna, Fabrice Barlesi, +10 authors, Pierre-Jean Souquet.
ESMO Open, 2018 Aug 11; 3(5). PMID: 30094074    Free PMC article.
Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy.
Yiyi Yan, Anagha Bangalore Kumar, +4 authors, Haidong Dong.
Front Immunol, 2018 Aug 14; 9. PMID: 30100909    Free PMC article.
Highly Cited. Review.
Rethinking Gamma-secretase Inhibitors for Treatment of Non-small-Cell Lung Cancer: Is Notch the Target?
Sharon R Pine.
Clin Cancer Res, 2018 Aug 15; 24(24). PMID: 30104200    Free PMC article.
Review.
Review of checkpoint immunotherapy for the management of non-small cell lung cancer.
Shine Raju, Ranjit Joseph, Sameep Sehgal.
Immunotargets Ther, 2018 Aug 15; 7. PMID: 30105218    Free PMC article.
Review.
The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer.
Fabio Gomes, Rebecca Tay, Jaseela Chiramel, Raffaele Califano.
Drugs Aging, 2018 Aug 15; 35(9). PMID: 30105645
Review.
Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer.
D E Meyers, P M Bryan, S Banerji, D G Morris.
Curr Oncol, 2018 Aug 17; 25(4). PMID: 30111979    Free PMC article.
Review.
Spindle Cell Carcinoma of the Lung/Pleura: An Incidental Finding.
Muhammad Sardar, Muhammad Azharuddin, +4 authors, Doantrang Du.
Cureus, 2018 Aug 25; 10(6). PMID: 30140599    Free PMC article.
Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan.
Jason C Hsu, Jia-Yu Lin, May-Ying Hsu, Peng-Chan Lin.
PLoS One, 2018 Aug 25; 13(8). PMID: 30142174    Free PMC article.
Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study.
Yukihiro Yano, Hiroyuki Kurebe, +10 authors, Masahide Mori.
PLoS One, 2018 Aug 29; 13(8). PMID: 30153300    Free PMC article.
Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Hongshu Sui, Ningxia Ma, +4 authors, Jiali Yang.
J Immunol Res, 2018 Aug 31; 2018. PMID: 30159341    Free PMC article.
Highly Cited. Review.
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
J K Sabari, G C Leonardi, +23 authors, A Drilon.
Ann Oncol, 2018 Aug 31; 29(10). PMID: 30165371    Free PMC article.
Highly Cited.
Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.
Daniela Cornelia Lazăr, Mihaela Flavia Avram, +3 authors, Adrian Goldiș.
World J Gastroenterol, 2018 Sep 01; 24(32). PMID: 30166856    Free PMC article.
Highly Cited. Review.
Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study.
Melin J Khandekar, Rakesh Jain.
Transl Cancer Res, 2018 Sep 04; 7(Suppl 1). PMID: 30175050    Free PMC article.
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Roberto Ferrara, Laura Mezquita, +25 authors, Caroline Caramella.
JAMA Oncol, 2018 Sep 08; 4(11). PMID: 30193240    Free PMC article.
Highly Cited.
New advances in immunotherapy for non-small cell lung cancer.
Haifeng Qin, Fang Wang, +4 authors, Hongjun Gao.
Am J Transl Res, 2018 Sep 14; 10(8). PMID: 30210667    Free PMC article.
Review.
New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1.
Nicolas Villanueva, Lyudmila Bazhenova.
Ther Adv Respir Dis, 2018 Sep 15; 12. PMID: 30215300    Free PMC article.
Review.
Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer.
Shuai Wang, Jiatao Hao, +2 authors, Lijie Tan.
Oncoimmunology, 2018 Sep 18; 7(8). PMID: 30221052    Free PMC article.
Autochthonous murine models for the study of smoker and never-smoker associated lung cancers.
Esra A Akbay, James Kim.
Transl Lung Cancer Res, 2018 Sep 19; 7(4). PMID: 30225211    Free PMC article.
Review.
Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.
Francesco Facchinetti, Paola Bordi, +2 authors, Marcello Tiseo.
Drug Des Devel Ther, 2018 Sep 22; 12. PMID: 30237696    Free PMC article.
Review.
PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer.
David D Stenehjem, Dao Tran, Michael A Nkrumah, Shilpa Gupta.
Onco Targets Ther, 2018 Oct 03; 11. PMID: 30275703    Free PMC article.
Review.
Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment.
Hongge Liang, Xiaoyan Liu, Mengzhao Wang.
Onco Targets Ther, 2018 Oct 06; 11. PMID: 30288054    Free PMC article.
Review.
Granulin A Synergizes with Cisplatin to Inhibit the Growth of Human Hepatocellular Carcinoma.
Gan Qiao, Huanli Xu, +7 authors, Xiukun Lin.
Int J Mol Sci, 2018 Oct 12; 19(10). PMID: 30301274    Free PMC article.
Potential Regulatory Roles of MicroRNAs and Long Noncoding RNAs in Anticancer Therapies.
Mengyan Xie, Ling Ma, +4 authors, Yongqian Shu.
Mol Ther Nucleic Acids, 2018 Oct 15; 13. PMID: 30317163    Free PMC article.
Review.
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients.
Marius Ilié, Mélanie Ngo-Mai, +6 authors, Paul Hofman.
J Vis Exp, 2018 Oct 16; (139). PMID: 30320751    Free PMC article.
Durvalumab in NSCLC: latest evidence and clinical potential.
Nerea Muñoz-Unceta, Isabel Burgueño, Elizabeth Jiménez, Luis Paz-Ares.
Ther Adv Med Oncol, 2018 Oct 23; 10. PMID: 30344651    Free PMC article.
Review.
Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial.
Christophe Le Tourneau, Christopher Hoimes, +9 authors, James L Gulley.
J Immunother Cancer, 2018 Oct 24; 6(1). PMID: 30348224    Free PMC article.
Highly Cited.
We should be done in such a way that patients with stage IV non-small cell lung cancer who would benefit from surgery are not overlooked.
Yasuhiro Chikaishi, Ayako Hirai, +2 authors, Fumihiro Tanaka.
J Thorac Dis, 2018 Oct 30; 10(Suppl 26). PMID: 30370131    Free PMC article.
Is more the better?-cetuximab in non-small cell lung cancer patients.
Teresa Moran.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393599    Free PMC article.
Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?
Niki Karachaliou, Manuel Fernandez-Bruno, Rafael Rosell.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393600    Free PMC article.
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
Cheng Xu, Yu-Pei Chen, +12 authors, Jun Ma.
BMJ, 2018 Nov 10; 363. PMID: 30409774    Free PMC article.
Highly Cited. Systematic Review.
Moving away (finally) from doublet therapy in lung cancer: immunotherapy and KEYNOTE-189.
Sheenu Sheela, Edward S Kim, Kathryn F Mileham.
J Thorac Dis, 2018 Nov 13; 10(9). PMID: 30416764    Free PMC article.
Immunotherapy strategy of EGFR mutant lung cancer.
Shaorong Yu, Delin Liu, +2 authors, Jifeng Feng.
Am J Cancer Res, 2018 Nov 13; 8(10). PMID: 30416860    Free PMC article.
Immunotherapy in Advanced Non-small Cell Lung Cancer Patients: Ushering Chemotherapy Through the Checkpoint Inhibitors?
Bushra Kanwal, Sharmi Biswas, Robert S Seminara, Charan Jeet.
Cureus, 2018 Nov 13; 10(9). PMID: 30416904    Free PMC article.
Review.
Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report.
Haibo Mou, Lanfang Yu, +8 authors, Kai Wang.
BMC Cancer, 2018 Nov 14; 18(1). PMID: 30419854    Free PMC article.
The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis.
Min Peng, Xing Li, +3 authors, Qi Bin Song.
Onco Targets Ther, 2018 Nov 15; 11. PMID: 30425525    Free PMC article.
Review.
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
Shirish M Gadgeel, James P Stevenson, +12 authors, Vassiliki Papadimitrakopoulou.
Lung Cancer, 2018 Nov 16; 125. PMID: 30429032    Free PMC article.
Neoadjuvant PD-1 blockade in non-small cell lung cancer: what else do we need to do?
Wei Guo, Su Yang, +2 authors, Bo Lu.
J Thorac Dis, 2018 Nov 16; 10(Suppl 26). PMID: 30430027    Free PMC article.
Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?
Simon Heeke, Paul Hofman.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505707    Free PMC article.
Review.
Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC.
Niki Karachaliou, Manuel Fernandez-Bruno, Jillian Wilhelmina Paulina Bracht, Rafael Rosell.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505714    Free PMC article.
Review.
An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer.
Alexander Liede, Rohini K Hernandez, +5 authors, Mark J Smyth.
Oncoimmunology, 2018 Dec 14; 7(12). PMID: 30524886    Free PMC article.
Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies.
Kazuhiro Togasaki, Yasutaka Sukawa, Takanori Kanai, Hiromasa Takaishi.
Onco Targets Ther, 2018 Dec 13; 11. PMID: 30538493    Free PMC article.
Review.
Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
Ammar Sukari, Misako Nagasaka, +9 authors, Shirish Gadgeel.
Anticancer Res, 2019 Feb 04; 39(2). PMID: 30711957    Free PMC article.
Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.
Sayuri Miyauchi, Sangwoo S Kim, +6 authors, Andrew B Sharabi.
Clin Cancer Res, 2019 Mar 01; 25(14). PMID: 30814108    Free PMC article.
Review.
From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer.
Deepa Rangachari, Daniel B Costa.
J Clin Oncol, 2019 Jun 04; 37(28). PMID: 31154918    Free PMC article.
Application of PD-1 Blockade in Cancer Immunotherapy.
Xiaomo Wu, Zhongkai Gu, +4 authors, Xiaolong Liu.
Comput Struct Biotechnol J, 2019 Jun 18; 17. PMID: 31205619    Free PMC article.
Highly Cited. Review.
Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Jingjing Liu, Shuang Li, +7 authors, Ying Cheng.
J Clin Lab Anal, 2019 Jul 10; 33(8). PMID: 31282096    Free PMC article.
Highly Cited.
Imaging of Precision Therapy for Lung Cancer: Current State of the Art.
Hyesun Park, Lynette M Sholl, +2 authors, Mizuki Nishino.
Radiology, 2019 Aug 07; 293(1). PMID: 31385753    Free PMC article.
Review.
Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer.
Danyang Sun, Junxun Ma, +16 authors, Yi Hu.
Cancer Immunol Immunother, 2019 Sep 20; 68(9). PMID: 31535160    Free PMC article.
Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Yu Chen, Gang Chen, +14 authors, Jian-Ji Pan.
JAMA Netw Open, 2019 Sep 21; 2(9). PMID: 31539077    Free PMC article.
A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors.
Misako Nagasaka, Nadine Abdallah, +6 authors, Ammar Sukari.
Lung Cancer (Auckl), 2019 Oct 02; 10. PMID: 31572037    Free PMC article.
Immune checkpoint inhibitors for esophageal cancer: are we moving in the right direction?
Alexander G Raufi, Khaldoun Almhanna.
Ann Transl Med, 2019 Oct 03; 7(Suppl 3). PMID: 31576309    Free PMC article.
EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCARE®.
Konstantinos Sapalidis, Paul Zarogoulidis, +20 authors, Isaak Kesisoglou.
J Cancer, 2019 Oct 11; 10(20). PMID: 31598145    Free PMC article.
Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
Aung Myint Tun, Kyaw Zin Thein, Wai Lin Thein, Elizabeth Guevara.
Future Sci OA, 2019 Oct 15; 5(9). PMID: 31608159    Free PMC article.
Review.
Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis.
Ya-Fang Huang, Wen-Jie Xie, Hai-Yu Fan, Juan Du.
Front Oncol, 2019 Oct 22; 9. PMID: 31632907    Free PMC article.
Systematic Review.
The Diverse Function of PD-1/PD-L Pathway Beyond Cancer.
Weiting Qin, Lipeng Hu, +4 authors, Xu Wang.
Front Immunol, 2019 Oct 23; 10. PMID: 31636634    Free PMC article.
Highly Cited. Review.
Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors.
Muhammad Z Afzal, Konstantin Dragnev, Tayyaba Sarwar, Keisuke Shirai.
Lung Cancer Manag, 2019 Oct 28; 8(2). PMID: 31645894    Free PMC article.
Aberrant upregulation of PDK1 in ovarian cancer cells impairs CD8+ T cell function and survival through elevation of PD-L1.
Jing-Jing Wang, Michelle K Siu, +6 authors, Karen K Chan.
Oncoimmunology, 2019 Oct 28; 8(11). PMID: 31646108    Free PMC article.
Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists.
Sunhee Chang, Hyung Kyu Park, Yoon-La Choi, Se Jin Jang.
J Pathol Transl Med, 2019 Oct 28; 53(6). PMID: 31656061    Free PMC article.
Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer.
Guanghui Gao, Meng Qiao, +8 authors, Caicun Zhou.
J Thorac Dis, 2019 Oct 28; 11(9). PMID: 31656652    Free PMC article.
Recent advances and application of PD-1 blockade in sarcoma.
Wenli Zuo, Lingdi Zhao.
Onco Targets Ther, 2019 Nov 07; 12. PMID: 31692518    Free PMC article.
Immune checkpoint inhibitors in gastrointestinal malignancies: what can we learn from experience with other tumors?
Anand B Shah, Katelyn R Sommerer, Khaldoun Almhanna.
Transl Gastroenterol Hepatol, 2019 Nov 16; 4. PMID: 31728430    Free PMC article.
Review.
Neoadjuvant treatment with tyrosine kinase inhibitors in patients with resectable non-small cell lung cancer.
Fernando Franco, Mariano Provencio.
J Thorac Dis, 2019 Nov 19; 11(10). PMID: 31737290    Free PMC article.
Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients.
Takuya Aoki, Takeshi Akiba, +21 authors, Koichiro Asano.
Respir Res, 2019 Nov 23; 20(1). PMID: 31752884    Free PMC article.
Immune-Checkpoint Inhibitors as the First Line Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Yuqiao Chen, Yuan Zhou, +4 authors, Wei Zhuang.
J Cancer, 2019 Nov 28; 10(25). PMID: 31772659    Free PMC article.
Review.
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC.
Marika Cinausero, Noemi Laprovitera, +13 authors, Andrea Ardizzoni.
Ther Adv Med Oncol, 2019 Dec 05; 11. PMID: 31798692    Free PMC article.
Incidence and Risk of Thyroid Dysfunction in Advanced or Metastatic Non-small Cell Lung Cancer Patients Treated with Pembrolizumab: A Meta-analysis.
Haisam Abid, Maryam Khavandi, +2 authors, Anush Patel.
Cureus, 2019 Dec 07; 11(10). PMID: 31807385    Free PMC article.
Review.
Conversion therapy from N3 unresectable lung adenocarcinoma to radical surgery: a case report.
Huali Hu, Shuai Zou, +4 authors, Aihui Liao.
Ann Transl Med, 2019 Dec 07; 7(20). PMID: 31807571    Free PMC article.
Review.
Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer.
Carmine Carbone, Geny Piro, +9 authors, Emilio Bria.
Mediators Inflamm, 2019 Dec 13; 2019. PMID: 31827379    Free PMC article.
Review.
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.
Min Yuan, Li-Li Huang, +2 authors, Qing Xu.
Signal Transduct Target Ther, 2019 Dec 25; 4. PMID: 31871778    Free PMC article.
Highly Cited. Review.
Immunotherapy and next-generation sequencing guided therapy for precision oncology: What have we learnt and what does the future hold?
Roman Groisberg, Vivek Subbiah.
Expert Rev Precis Med Drug Dev, 2018 Jan 01; 3(3). PMID: 31886407    Free PMC article.
Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens.
Lei Zhao, Jing Yu, +3 authors, Bangwei Cao.
J Cancer, 2020 Jan 02; 11(1). PMID: 31892971    Free PMC article.
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.
Shetal A Patel, Andy J Minn.
Immunity, 2018 Mar 22; 48(3). PMID: 29562193    Free PMC article.
Highly Cited. Review.
Safety outcomes in advanced non-small-cell lung cancer patients treated with first-line platinum-based regimens in the United States.
Lei Chen, Jong Seok Kim, +3 authors, William John.
J Thorac Dis, 2020 Jan 07; 11(11). PMID: 31903235    Free PMC article.
[Progress of Steroids Effect on Efficacy of Immune Checkpoint Inhibitors].
Guoqiang Pan, Yun Fan.
Zhongguo Fei Ai Za Zhi, 2019 Dec 26; 22(12). PMID: 31874675    Free PMC article.
Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies.
Jingli Lu, Jing Yang, +3 authors, Xiaojian Zhang.
Front Pharmacol, 2020 Jan 11; 10. PMID: 31920646    Free PMC article.
Systematic Review.
Distribution of PD-L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected non-small cell lung cancer.
Qian Chen, Yi-Yun Fu, +5 authors, Li-Li Jiang.
Int J Clin Exp Pathol, 2020 Jan 15; 12(3). PMID: 31933885    Free PMC article.
Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer.
Fan Zhang, Di Huang, +13 authors, Yi Hu.
J Cancer, 2020 Jan 17; 11(3). PMID: 31942197    Free PMC article.
Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
Barbara Melosky, Rosalyn Juergens, +5 authors, Quincy Chu.
Oncologist, 2019 May 30; 25(1). PMID: 31138727    Free PMC article.
Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy.
Michael A Morse, Howard Hochster, Al Benson.
Oncologist, 2019 Aug 07; 25(1). PMID: 31383813    Free PMC article.
Review.
Odds ratio of programmed cell death-1 or ligand 1 inhibitor-related endocrine dysfunction in patients with lung cancer: A systematic review and meta-analysis.
Jian Xie, Zewen Zhang, +4 authors, Yuan Tian.
Medicine (Baltimore), 2019 Dec 20; 98(50). PMID: 31852114    Free PMC article.
Systematic Review.
Pembrolizumab - emerging treatment of pulmonary sarcomatoid carcinoma: A case report.
Emanuela Cimpeanu, Jibran Ahmed, +4 authors, Dennis Bloomfield.
World J Clin Cases, 2020 Jan 24; 8(1). PMID: 31970174    Free PMC article.
Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries.
Biancamaria Cembrola, Valentino Ruzza, +13 authors, Alfredo Nicosia.
Biomed Res Int, 2020 Jan 25; 2019. PMID: 31976323    Free PMC article.
Cancer immunotherapy experience in the Integral Oncology Centre "Diana Laura Riojas de Colosio", Médica Sur Hospital.
Ricardo Fernández-Ferreira, Daniel Motola-Kuba, +2 authors, María Eugenia Torres-Pérez.
Contemp Oncol (Pozn), 2020 Jan 30; 23(4). PMID: 31992957    Free PMC article.
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.
Wungki Park, Laura Mezquita, +14 authors, Gilberto Lopes.
Br J Cancer, 2019 Nov 26; 122(3). PMID: 31761899    Free PMC article.
Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations.
Elisabeth Smolle, Katharina Leithner, Horst Olschewski.
Thorac Cancer, 2019 Dec 05; 11(2). PMID: 31799812    Free PMC article.
Review.
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).
Alejandro Ruiz-Patiño, Oscar Arrieta, +28 authors, CLICaP.
Thorac Cancer, 2019 Dec 13; 11(2). PMID: 31828967    Free PMC article.
Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018.
Zhengyang Hu, Ming Li, +3 authors, Qun Wang.
Transl Lung Cancer Res, 2020 Feb 06; 8(6). PMID: 32010587    Free PMC article.
Review.
Is there a role for immunotherapy in ovarian cancer?
Gaia Giannone, Giorgio Valabrega.
Ann Transl Med, 2020 Feb 06; 7(Suppl 8). PMID: 32015995    Free PMC article.
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Jianchun Duan, Longgang Cui, +17 authors, Jie Wang.
JAMA Oncol, 2019 Dec 27; 6(3). PMID: 31876895    Free PMC article.
Systematic Review.
Comparative Effectiveness of Proton vs Photon Therapy as Part of Concurrent Chemoradiotherapy for Locally Advanced Cancer.
Brian C Baumann, Nandita Mitra, +10 authors, James M Metz.
JAMA Oncol, 2019 Dec 27; 6(2). PMID: 31876914    Free PMC article.
Immunotherapy in Ovarian Cancer.
Weimin Wang, Janice Rebecca Liu, Weiping Zou.
Surg Oncol Clin N Am, 2019 May 14; 28(3). PMID: 31079799    Free PMC article.
Review.
The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Chengdi Wang, Wenliang Qiao, +5 authors, Weimin Li.
J Cell Physiol, 2019 Nov 07; 235(5). PMID: 31693178    Free PMC article.
Systematic Review.
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
Edward B Garon, Giorgio Vittorio Scagliotti, +17 authors, Maurice Pérol.
ESMO Open, 2020 Jan 21; 5(1). PMID: 31958290    Free PMC article.
PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models.
Takahiro Yamazaki, Aitziber Buqué, Tyler D Ames, Lorenzo Galluzzi.
Oncoimmunology, 2020 Mar 03; 9(1). PMID: 32117585    Free PMC article.
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.
Giulia C Leonardi, Justin F Gainor, +8 authors, Mark M Awad.
J Clin Oncol, 2018 May 11; 36(19). PMID: 29746230    Free PMC article.
Highly Cited.
Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications.
Tanner Smida, Tullia C Bruno, Laura P Stabile.
Front Oncol, 2020 Mar 07; 10. PMID: 32133288    Free PMC article.
Review.
Autoimmune haemolytic anaemia in a patient with advanced lung adenocarcinoma and chronic lymphocytic leukaemia receiving nivolumab and intravenous immunoglobulin.
Sandra D Algaze, Wungki Park, Thomas J Harrington, Raja Mudad.
BMJ Case Rep, 2018 Mar 11; 2018. PMID: 29523604    Free PMC article.
Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.
Howard L Kaufman, Lawrence H Schwartz, +5 authors, Andrea Vergara-Silva.
J Cancer Res Clin Oncol, 2018 Aug 23; 144(11). PMID: 30132118
Systematic Review.
Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.
Karthik Suresh, Jarushka Naidoo, Cheng Ting Lin, Sonye Danoff.
Chest, 2018 Sep 07; 154(6). PMID: 30189190    Free PMC article.
Highly Cited. Review.
Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
Hui Yu, Zhengming Chen, +21 authors, Fred R Hirsch.
J Thorac Oncol, 2018 Sep 27; 14(1). PMID: 30253973    Free PMC article.
Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer?
Sarah B Goldberg, Roy S Herbst.
Cancer, 2018 Nov 02; 124(24). PMID: 30383887    Free PMC article.
Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient?
Zeina Al-Mansour, Linda Pang, Venu Bathini.
Drugs Aging, 2018 Nov 28; 36(1). PMID: 30478744
Review.
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.
Yixin Zhou, Chen Chen, +10 authors, Li Zhang.
J Immunother Cancer, 2018 Dec 24; 6(1). PMID: 30577837    Free PMC article.
Systematic Review.
A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.
Bishal Gyawali, Spencer Phillips Hey, Aaron S Kesselheim.
JAMA Netw Open, 2019 Jan 16; 1(2). PMID: 30646078    Free PMC article.
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
Jeffrey M Conroy, Sarabjot Pabla, +37 authors, Carl Morrison.
J Immunother Cancer, 2019 Jan 27; 7(1). PMID: 30678715    Free PMC article.
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Rui Chen, Xiaoming Hou, Liping Yang, Da Zhao.
Thorac Cancer, 2019 Feb 09; 10(4). PMID: 30734504    Free PMC article.
Systematic Review.
Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases.
Dennis P O'Malley, Yuhang Yang, +6 authors, Lawrence M Weiss.
Mod Pathol, 2019 Feb 15; 32(7). PMID: 30760860    Free PMC article.
Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Qiang Su, Emily C Zhu, +4 authors, Zu-Hua Gao.
Front Immunol, 2019 Feb 20; 10. PMID: 30778352    Free PMC article.
Systematic Review.
CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Marina Martinez, Edmund Kyung Moon.
Front Immunol, 2019 Feb 26; 10. PMID: 30804938    Free PMC article.
Highly Cited. Review.
Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients.
Ayako Shiono, Kyoichi Kaira, +8 authors, Hiroshi Kagamu.
Thorac Cancer, 2019 Feb 28; 10(4). PMID: 30809973    Free PMC article.
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Liliang Xia, Yuanyong Liu, Ying Wang.
Oncologist, 2019 Mar 02; 24(Suppl 1). PMID: 30819829    Free PMC article.
Review.
Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.
Deborah B Doroshow, Miguel F Sanmamed, +6 authors, Roy S Herbst.
Clin Cancer Res, 2019 Mar 03; 25(15). PMID: 30824587    Free PMC article.
Highly Cited. Review.
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
Yung-Jue Bang, Yoon-Koo Kang, +16 authors, Hyun Cheol Chung.
Gastric Cancer, 2019 Mar 27; 22(4). PMID: 30911859    Free PMC article.
Highly Cited.
Emerging therapies for non-small cell lung cancer.
Chao Zhang, Natasha B Leighl, Yi-Long Wu, Wen-Zhao Zhong.
J Hematol Oncol, 2019 Apr 27; 12(1). PMID: 31023335    Free PMC article.
Highly Cited. Review.
Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Zi-Xian Wang, Hao-Xiang Wu, +10 authors, Rui-Hua Xu.
JAMA Netw Open, 2019 May 06; 2(5). PMID: 31050784    Free PMC article.
Systematic Review.
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
Yixin Zhou, Zuan Lin, +4 authors, Li Zhang.
J Immunother Cancer, 2019 May 06; 7(1). PMID: 31053172    Free PMC article.
NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance.
Xiaoguang Li, Zhida Liu, +8 authors, Yang-Xin Fu.
Nat Commun, 2019 Jul 22; 10(1). PMID: 31324798    Free PMC article.
Platinum Derivatives Effects on Anticancer Immune Response.
Cédric Rébé, Lucie Demontoux, Thomas Pilot, François Ghiringhelli.
Biomolecules, 2019 Dec 22; 10(1). PMID: 31861811    Free PMC article.
Review.
Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.
Kei Kunimasa, Taichiro Goto.
Int J Mol Sci, 2020 Jan 23; 21(2). PMID: 31963413    Free PMC article.
Review.
Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review.
Nagla Abdel Karim, Karen Kelly.
Oncologist, 2019 Mar 28; 24(9). PMID: 30914465    Free PMC article.
Review.
Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer.
Shiqiang Wang, Chongling Hu, Fei Xie, Yanhui Liu.
Onco Targets Ther, 2020 Mar 12; 13. PMID: 32158220    Free PMC article.
Review.
Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study.
Zhichao Tian, Yonghao Yang, +5 authors, Jiaqiang Wang.
Cancer Manag Res, 2020 Mar 12; 12. PMID: 32158266    Free PMC article.
Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center.
Evan Hall, Jenny Zhang, +4 authors, Sunil Reddy.
Cancer Med, 2020 Jan 30; 9(6). PMID: 31994335    Free PMC article.
[Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer].
Hanfei Guo, Rilan Bai, Jiuwei Cui.
Zhongguo Fei Ai Za Zhi, 2020 Feb 26; 23(2). PMID: 32093454    Free PMC article.
Review.
Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
Meizhuo Gao, Tie Wang, +3 authors, Hongjiang Song.
Front Immunol, 2020 Mar 21; 11. PMID: 32194569    Free PMC article.
T cell recruitment triggered by optimal dose platinum compounds contributes to the therapeutic efficacy of sequential PD-1 blockade in a mouse model of colon cancer.
Deqiang Fu, Jichun Wu, +4 authors, Qiuyu Zhang.
Am J Cancer Res, 2020 Mar 21; 10(2). PMID: 32195021    Free PMC article.
Immune regulation and cytotoxic T cell activation of IL-10 agonists - Preclinical and clinical experience.
Martin Oft.
Semin Immunol, 2019 Nov 11; 44. PMID: 31706853    Free PMC article.
Review.
Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy.
Rama Soundararajan, Jared J Fradette, +18 authors, Sendurai A Mani.
Cancers (Basel), 2019 May 30; 11(5). PMID: 31137625    Free PMC article.
Review.
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.
D Isla, J de Castro, +5 authors, J M Trigo.
Clin Transl Oncol, 2019 Aug 02; 22(5). PMID: 31368078
Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept.
Thierry Berghmans, Valérie Durieux, Lizza E L Hendriks, Anne-Marie Dingemans.
Front Med (Lausanne), 2020 Apr 09; 7. PMID: 32266275    Free PMC article.
Systematic Review.
Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
Thaiz Rivera Vargas, Lionel Apetoh.
Front Immunol, 2019 Jun 14; 10. PMID: 31191545    Free PMC article.
Review.
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.
Raju K Vaddepally, Prakash Kharel, +2 authors, Abhinav B Chandra.
Cancers (Basel), 2020 Apr 05; 12(3). PMID: 32245016    Free PMC article.
Review.
Rational application of the first-line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta-analysis.
Rui Cao, Jie-Tao Ma, +6 authors, Cheng-Bo Han.
Cancer Med, 2019 Jul 13; 8(11). PMID: 31297962    Free PMC article.
Bone Marrow Findings of Immune-Mediated Pure Red Cell Aplasia Following Anti-Programmed Cell Death Receptor-1 Therapy: A Report of Two Cases and Review of Literature.
Le Le Aye, James B Harris, Imran Siddiqi, Ashley Hagiya.
J Hematol, 2020 Apr 18; 8(2). PMID: 32300448    Free PMC article.
Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer.
James W Opzoomer, Dominika Sosnowska, +2 authors, James N Arnold.
Front Immunol, 2019 Aug 06; 10. PMID: 31379850    Free PMC article.
Review.
Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
Jeffrey C Thompson, Wei-Ting Hwang, +9 authors, Steven M Albelda.
Lung Cancer, 2019 Nov 05; 139. PMID: 31683225    Free PMC article.
Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis.
Jie Liu, Chengming Li, +2 authors, Xue Meng.
Oncoimmunology, 2020 Apr 22; 9(1). PMID: 32313723    Free PMC article.
Systematic Review.
Recent Progress of Potentiating Immune Checkpoint Blockade with External Stimuli-an Industry Perspective.
Jun Xu, Robert Saklatvala, +2 authors, Adam Procopio.
Adv Sci (Weinh), 2020 Apr 25; 7(8). PMID: 32328428    Free PMC article.
Review.
Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer.
Chung-Shien Lee, Craig E Devoe, +2 authors, Nagashree Seetharamu.
Lung Cancer Manag, 2020 Apr 30; 9(2). PMID: 32346405    Free PMC article.
Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer.
Nobumasa Tamura, Hidehito Horinouchi, +7 authors, Yuichiro Ohe.
Thorac Cancer, 2019 Mar 27; 10(5). PMID: 30913364    Free PMC article.
Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors.
Menno Tamminga, Sanne de Wit, +4 authors, Harry J M Groen.
J Immunother Cancer, 2019 Jul 12; 7(1). PMID: 31291995    Free PMC article.
Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Christina A Hartl, Adrian Bertschi, +5 authors, Michael S Goldberg.
J Immunother Cancer, 2019 Aug 01; 7(1). PMID: 31362778    Free PMC article.
FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer.
Yue Guan, Sean G Kraus, +3 authors, Emma Teixeiro.
Front Oncol, 2020 May 12; 10. PMID: 32391270    Free PMC article.
Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment.
Angela Flavia Serpico, Roberta Visconti, Domenico Grieco.
Cell Death Dis, 2020 May 14; 11(5). PMID: 32398657    Free PMC article.
Review.
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors.
Praveen Vikas, Nicholas Borcherding, Adithya Chennamadhavuni, Rohan Garje.
Front Oncol, 2020 May 28; 10. PMID: 32457830    Free PMC article.
Review.
The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis.
Run-Cong Nie, Chong-Bang Zhao, +6 authors, Yuan-Fang Li.
Biomed Res Int, 2020 May 29; 2020. PMID: 32461994    Free PMC article.
Systematic Review.
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yunfang Yu, Dongqiang Zeng, +8 authors, Herui Yao.
JAMA Netw Open, 2019 Jul 11; 2(7). PMID: 31290993    Free PMC article.
Highly Cited.
Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach.
Michail Nikolaou, Georgios Nikolaou, +4 authors, Maria Tolia.
Integr Cancer Ther, 2019 Feb 23; 18. PMID: 30791740    Free PMC article.
Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer.
Jia-Xin Li, Ju-Min Huang, +4 authors, Pei-Yu Yan.
Integr Cancer Ther, 2019 Dec 17; 18. PMID: 31838881    Free PMC article.
Review.
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
Joseph Tintelnot, Eray Goekkurt, +14 authors, Alexander Stein.
BMC Cancer, 2020 Jun 04; 20(1). PMID: 32487035    Free PMC article.
PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake.
Jian-Ye Zhang, Yan-Yan Yan, +2 authors, Li-Wu Fu.
Front Pharmacol, 2020 Jun 13; 11. PMID: 32528284    Free PMC article.
Review.
Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer.
Shintaro Kanda, Yuichiro Ohe, +6 authors, Tomohide Tamura.
Cancer Sci, 2020 Apr 12; 111(6). PMID: 32277531    Free PMC article.
Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer.
Michael S Leapman, Carolyn J Presley, +5 authors, Cary P Gross.
JAMA Netw Open, 2020 Jun 09; 3(6). PMID: 32511721    Free PMC article.
Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy.
Feng Xie, Jianjun Zhang, +25 authors, Tian Xia.
Clin Cancer Res, 2020 Jan 09; 26(12). PMID: 31911545    Free PMC article.
The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Extrapulmonary Small Cell Carcinoma.
Ragia Aly, Sachin Gupta, Rashmika Potdar.
Cureus, 2020 Jul 04; 12(6). PMID: 32617246    Free PMC article.
Review.
Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients.
Jesus Vera Aguilera, Jonas Paludo, +10 authors, Yiyi Yan.
Melanoma Res, 2020 May 15; 30(4). PMID: 32404734    Free PMC article.
Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma.
Lin Shui, Ke Cheng, +7 authors, Dan Cao.
Front Immunol, 2020 Jul 09; 11. PMID: 32636837    Free PMC article.
Development of a Pemetrexed/Folic Acid Nanoformulation: Synthesis, Characterization, and Efficacy in a Murine Colorectal Cancer Model.
Justin G Rosch, Allison N DuRoss, Madeleine R Landry, Conroy Sun.
ACS Omega, 2020 Jul 09; 5(25). PMID: 32637817    Free PMC article.
Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial.
Yong Song, Liyun Miao, Zhaoxia Wang, Meiqi Shi.
J Thorac Dis, 2020 Jul 10; 12(5). PMID: 32642151    Free PMC article.
Bronchoscopic tissue yield for advanced molecular testing: are we getting enough?
Pattraporn Tajarernmuang, Linda Ofiara, Stéphane Beaudoin, Anne V Gonzalez.
J Thorac Dis, 2020 Jul 10; 12(6). PMID: 32642252    Free PMC article.
Review.
Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
Lin Shui, Ke Cheng, +5 authors, Dan Cao.
BMC Cancer, 2020 Jul 11; 20(1). PMID: 32646394    Free PMC article.
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.
Gaia Giannone, Eleonora Ghisoni, +4 authors, Giorgio Valabrega.
Int J Mol Sci, 2020 Jun 25; 21(12). PMID: 32575899    Free PMC article.
Review.
Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy.
Fan Zhang, Di Huang, +14 authors, Yi Hu.
Ther Adv Med Oncol, 2020 Jul 17; 12. PMID: 32670420    Free PMC article.
The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.
Yu Wang, Qingguo Sun, +5 authors, Xiangguo Liu.
Cell Commun Signal, 2020 Jul 16; 18(1). PMID: 32665011    Free PMC article.
The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung.
Yoshinobu Ichiki, Takashi Fukuyama, Kozo Nakanishi.
Transl Lung Cancer Res, 2020 Jul 18; 9(3). PMID: 32676343    Free PMC article.
Immunotherapies and Metastatic Cancers: Understanding Utility and Predictivity of Human Immune Cell Engrafted Mice in Preclinical Drug Development.
Tiina E Kähkönen, Jussi M Halleen, Jenni Bernoulli.
Cancers (Basel), 2020 Jun 24; 12(6). PMID: 32570871    Free PMC article.
Review.
Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy.
Meilin Jiang, Wenying Peng, +11 authors, Lin Wu.
Front Oncol, 2020 Jul 23; 10. PMID: 32695663    Free PMC article.
Immunotherapy - new perspective in lung cancer.
Fillipe Dantas Pinheiro, Adriano Fernandes Teixeira, +3 authors, Fabrício Freire de Melo.
World J Clin Oncol, 2020 Jul 31; 11(5). PMID: 32728528    Free PMC article.
Review.
SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
Yu Chen, Min Gao, +2 authors, Xiangjiao Meng.
J Hematol Oncol, 2020 Jul 30; 13(1). PMID: 32723363    Free PMC article.
Review.
Sequential Whole Exome Sequencing Reveals Somatic Mutations Associated with Platinum Response in NSCLC.
Ao-Xiang Guo, Fan Xiao, +5 authors, Ji-Ye Yin.
Onco Targets Ther, 2020 Aug 06; 13. PMID: 32753889    Free PMC article.
Rethinking clinical oncology drug research in an era of value-based cancer care: A role for chemotherapy pathways.
J Russell Hoverman.
Cancer Med, 2020 Jun 12; 9(15). PMID: 32524722    Free PMC article.
Review.
Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis.
Tingting Liu, Bo Jin, +4 authors, Guang Li.
Ther Adv Med Oncol, 2020 Aug 11; 12. PMID: 32774474    Free PMC article.
PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis.
Jorge García-González, Juan Ruiz-Bañobre, +12 authors, Luis León-Mateos.
J Clin Med, 2020 Jul 09; 9(7). PMID: 32635291    Free PMC article.
Review.
Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors.
Magalie Dosset, Elodie Lauret-Marie Joseph, Thaiz Rivera Vargas, Lionel Apetoh.
Cells, 2020 Jul 28; 9(7). PMID: 32707692    Free PMC article.
Review.
CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study.
Jyoti Mayadev, Ana T Nunes, +3 authors, Bradley J Monk.
Int J Gynecol Cancer, 2020 May 25; 30(7). PMID: 32447296    Free PMC article.
Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons.
Elisa Aquilanti, Priscilla K Brastianos.
Neurosurgery, 2020 Apr 18; 87(3). PMID: 32302389    Free PMC article.
Review.
Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer.
Wei Liu, Lei Zhang, +6 authors, Jianhui Cai.
Onco Targets Ther, 2020 Aug 18; 13. PMID: 32801752    Free PMC article.
Review.
A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies.
Jialin Qu, Li Wang, +5 authors, Xiaochun Zhang.
Cancer Manag Res, 2020 Aug 18; 12. PMID: 32801888    Free PMC article.
Review.
Consolidation radiotherapy for patients with extended disease small cell lung cancer in a single tertiary institution: impact of dose and perspectives in the era of immunotherapy.
Karmen Stanic, Martina Vrankar, Jasna But-Hadzic.
Radiol Oncol, 2020 Jul 30; 54(3). PMID: 32726294    Free PMC article.
The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer.
Joshua T Burgess, Maddison Rose, +7 authors, Emma Bolderson.
Front Oncol, 2020 Aug 28; 10. PMID: 32850380    Free PMC article.
Review.
New Understanding of the Relevant Role of LINE-1 Retrotransposition in Human Disease and Immune Modulation.
Xiao Zhang, Rui Zhang, Jinpu Yu.
Front Cell Dev Biol, 2020 Aug 28; 8. PMID: 32850797    Free PMC article.
Review.
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.
David R Spigel, Jamie E Chaft, +11 authors, Naiyer A Rizvi.
J Thorac Oncol, 2018 May 19; 13(11). PMID: 29775807    Free PMC article.
Primary Gastric Adenosquamous Carcinoma: A Case Report.
Ragia Aly, Sachin Gupta, +3 authors, Balraj Singh.
Gastroenterology Res, 2020 Aug 31; 13(4). PMID: 32864027    Free PMC article.
[Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].
Di Zhang, Jiaqi Huang, +2 authors, Qisen Guo.
Zhongguo Fei Ai Za Zhi, 2019 Jun 15; 22(6). PMID: 31196371    Free PMC article.
Review.
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.
Ana Bocanegra, Ester Blanco, +7 authors, Grazyna Kochan.
Int J Mol Sci, 2020 Aug 23; 21(16). PMID: 32824655    Free PMC article.
Review.
Pembrolizumab-induced pancytopenia in a patient with squamous cell lung cancer.
Yuriko Ueki, Manabu Suzuki, +19 authors, Haruhito Sugiyama.
Thorac Cancer, 2020 Aug 09; 11(9). PMID: 32767641    Free PMC article.
Molecular mechanisms and clinical implications of miRNAs in drug resistance of colorectal cancer.
Lili Duan, Wanli Yang, +11 authors, Daiming Fan.
Ther Adv Med Oncol, 2020 Sep 15; 12. PMID: 32922521    Free PMC article.
Review.
ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer.
Zheng Liu, Kejia Zhao, +9 authors, Lunxu Liu.
Oncoimmunology, 2020 Sep 15; 9(1). PMID: 32923114    Free PMC article.
Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Gernot Wagner, Hannah Karolina Stollenwerk, +3 authors, Josef Singer.
Oncoimmunology, 2020 Sep 15; 9(1). PMID: 32923134    Free PMC article.
Systematic Review.
[First-line Combination Immunotherapy in Advanced Non-small Cell Lung Cancer].
Xiaoxiao Peng, Qing Zhou.
Zhongguo Fei Ai Za Zhi, 2018 Dec 29; 21(12). PMID: 30591101    Free PMC article.
Review.
Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis.
Boris Shulgin, Yuri Kosinsky, +8 authors, Gabriel Helmlinger.
Oncoimmunology, 2020 Sep 17; 9(1). PMID: 32934874    Free PMC article.
Review.
Challenges of PD-L1 testing in non-small cell lung cancer and beyond.
Minyu Wang, Sen Wang, Joseph A Trapani, Paul J Neeson.
J Thorac Dis, 2020 Sep 19; 12(8). PMID: 32944371    Free PMC article.
Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?
Toyoaki Hida, Teppei Yamaguchi.
J Thorac Dis, 2020 Sep 19; 12(8). PMID: 32944372    Free PMC article.
Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy.
Young Kwang Chae, Won Bin Kim, +11 authors, Pedro Viveiros.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953481    Free PMC article.
A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians.
Siyu Peng, Ariel Fangting Ying, Bee Choo Tai, Ross Andrew Soo.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953491    Free PMC article.
Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis.
Jiaqi Liang, Ming Li, +7 authors, Lijie Tan.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953506    Free PMC article.
The clinical promise of immunotherapy in triple-negative breast cancer.
Praveen Vikas, Nicholas Borcherding, Weizhou Zhang.
Cancer Manag Res, 2018 Dec 24; 10. PMID: 30573992    Free PMC article.
Review.
VEGF inhibitors in EGFR-mutated lung cancer: a never-ending story?
Mariam Alexander, Balazs Halmos.
Ann Transl Med, 2019 Jan 04; 6(23). PMID: 30603634    Free PMC article.
Treatment of induction in resectable NSCLC with chemotherapy, followed by surgery and erlotinib.
Fernando Franco, Mariano Provencio.
Ann Transl Med, 2019 Jan 08; 6(Suppl 1). PMID: 30613606    Free PMC article.
Evaluation of combined anti-PD-1 immunotherapy and radiation therapy in a preclinical mouse model of pneumonitis and fibrosis.
Derek Nichols, Theresa A Boyle, +6 authors, Bradford A Perez.
J Thorac Dis, 2019 Jan 10; 10(11). PMID: 30622798    Free PMC article.
Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey.
Valentina Bertaglia, Stefania Vallone, Maria Vittoria Pacchiana, Silvia Novello.
Lung Cancer Manag, 2019 Jan 16; 6(3). PMID: 30643575    Free PMC article.
Review.
Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis.
Marcelo Bonomi, Tamjeed Ahmed, +7 authors, Pierre L Triozzi.
Oncol Lett, 2019 Jan 19; 17(1). PMID: 30655905    Free PMC article.
Statins improve survival in patients previously treated with nivolumab for advanced non-small cell lung cancer: An observational study.
Miwako Omori, Yusuke Okuma, Taiki Hakozaki, Yukio Hosomi.
Mol Clin Oncol, 2019 Jan 19; 10(1). PMID: 30655989    Free PMC article.
VISTA/PD-1H: a potential target for non-small cell lung cancer immunotherapy.
Juan-Manuel Hernandez-Martinez, Edgar Vergara, +2 authors, Oscar Arrieta.
J Thorac Dis, 2019 Feb 13; 10(12). PMID: 30746169    Free PMC article.
Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis.
Kaikai Shen, Jinggang Cui, +8 authors, Dang Lin.
J Thorac Dis, 2019 Feb 13; 10(12). PMID: 30746209    Free PMC article.
Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line - Indian consensus statement update.
Kumar Prabhash.
South Asian J Cancer, 2019 Feb 16; 8(1). PMID: 30766843    Free PMC article.
Review.
Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update.
Hélène Blons, Simon Garinet, Pierre Laurent-Puig, Jean-Baptiste Oudart.
J Thorac Dis, 2019 Feb 19; 11(Suppl 1). PMID: 30775025    Free PMC article.
Review.
Chemotherapy for Lung Cancer in the Era of Personalized Medicine.
Seung Hyeun Lee.
Tuberc Respir Dis (Seoul), 2019 Mar 07; 82(3). PMID: 30841023    Free PMC article.
Review.
From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC.
Maria Protopapa, Vassilis Kouloulias, +3 authors, Anna Zygogianni.
J Oncol, 2019 Mar 12; 2019. PMID: 30853981    Free PMC article.
Review.
Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Yi Jiang, Ning Zhang, +2 authors, Helong Zhang.
Ther Clin Risk Manag, 2019 Mar 13; 15. PMID: 30858709    Free PMC article.
Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells.
Maxine Bauzon, Penelope M Drake, +3 authors, David Rabuka.
Oncoimmunology, 2019 Mar 25; 8(4). PMID: 30906660    Free PMC article.
Immunological Agents Used in Cancer Treatment.
Melih Simsek, Salim Basol Tekin, Mehmet Bilici.
Eurasian J Med, 2019 Mar 27; 51(1). PMID: 30911265    Free PMC article.
Review.
Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer.
Chongkai Wang, Prakash Kulkarni, Ravi Salgia.
Mol Ther Oncolytics, 2019 Apr 13; 13. PMID: 30976658    Free PMC article.
Review.
Mitochondrion-targeted platinum complexes suppressing lung cancer through multiple pathways involving energy metabolism.
Zhenzhu Zhu, Zenghui Wang, +5 authors, Xiaoyong Wang.
Chem Sci, 2019 Apr 19; 10(10). PMID: 30996891    Free PMC article.
The ABCs of preventing hyperprogressive disease after immunotherapy: awareness, biomarkers, and combination.
Kenichi Suda.
J Thorac Dis, 2019 Apr 19; 11(Suppl 3). PMID: 30997217    Free PMC article.
An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer.
Muhammad Zubair Afzal, Konstantin H Dragnev, Keisuke Shirai.
Ann Transl Med, 2019 Apr 30; 7(Suppl 1). PMID: 31032332    Free PMC article.
Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis.
Alfredo Addeo, Giuseppe Luigi Banna, Giulio Metro, Massimo Di Maio.
Front Oncol, 2019 May 07; 9. PMID: 31058078    Free PMC article.
Highly Cited. Systematic Review.
Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer.
Arik Bernard Schulze, Georg Evers, +4 authors, Lars Henning Schmidt.
Cancers (Basel), 2019 May 22; 11(5). PMID: 31108964    Free PMC article.
Review.
Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis.
Caiqing Zhang, Shuisheng Zhang, +5 authors, Yuan Tian.
Cancer Manag Res, 2019 May 24; 11. PMID: 31118808    Free PMC article.
Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB).
Fangping Ren, Tian Zhao, Bing Liu, Lei Pan.
Onco Targets Ther, 2019 Jun 27; 12. PMID: 31239702    Free PMC article.
Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer.
Frank Weinberg, Shirish Gadgeel.
Lung Cancer (Auckl), 2019 Jun 27; 10. PMID: 31239797    Free PMC article.
Programmed death ligand 1 (PD-L1) expression in parathyroid tumors.
Boju Pan, Anqi Wang, +4 authors, Zhiyong Liang.
Endocr Connect, 2019 Jun 30; 8(7). PMID: 31252398    Free PMC article.
A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer.
Ning Wan, Bo Ji, +4 authors, Wenjie Huang.
Onco Targets Ther, 2019 Jul 16; 12. PMID: 31303759    Free PMC article.
Review.
M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer.
Lili Cao, Xiaofang Che, +7 authors, Yunpeng Liu.
Cancer Manag Res, 2019 Jul 17; 11. PMID: 31308749    Free PMC article.
Smoking history influences the prognostic value of peripheral naïve CD4+ T cells in advanced non-small cell lung cancer.
Chao Liu, Bin Xu, +5 authors, Jinming Yu.
Cancer Cell Int, 2019 Jul 20; 19. PMID: 31320838    Free PMC article.
Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy.
Ruby Maharjan, Rudra Pangeni, +5 authors, Youngro Byun.
Pharmaceutics, 2019 Jul 25; 11(7). PMID: 31337061    Free PMC article.
Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice.
Sawsan Rashdan, David E Gerber.
Transl Lung Cancer Res, 2019 Aug 02; 8(3). PMID: 31367533    Free PMC article.
First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis.
Tingting Liu, Silu Ding, +3 authors, Guang Li.
J Thorac Dis, 2019 Aug 30; 11(7). PMID: 31463119    Free PMC article.
Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer.
Zhenbin Qiu, Zihao Chen, Chao Zhang, Wenzhao Zhong.
Exp Hematol Oncol, 2019 Aug 30; 8. PMID: 31463163    Free PMC article.
Review.
The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer.
Jia Li Low, Robert J Walsh, +2 authors, Ross A Soo.
Ther Adv Med Oncol, 2019 Sep 10; 11. PMID: 31497071    Free PMC article.
Review.
The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials.
Yangyang Xu, Bing Wan, +13 authors, written on behalf of AME Lung Cancer Collaborative Group.
Transl Lung Cancer Res, 2019 Sep 27; 8(4). PMID: 31555516    Free PMC article.
The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients.
Huijuan Li, Yangyang Xu, +12 authors, written on behalf of AME Lung Cancer Collaborative Group.
Transl Lung Cancer Res, 2019 Sep 27; 8(4). PMID: 31555517    Free PMC article.
Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis.
Xiaodi Guo, Wendong Li, +2 authors, Qiang Su.
Eur J Clin Pharmacol, 2020 Jun 09; 76(10). PMID: 32507925    Free PMC article.
Systematic Review.
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy.
Leilei Ai, Jian Chen, +4 authors, Xiaochun Yang.
Drug Des Devel Ther, 2020 Sep 29; 14. PMID: 32982171    Free PMC article.
Review.
Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper.
Fabio Gomes, Melisa Wong, +4 authors, Andrea Luciani.
Br J Cancer, 2020 Jul 23; 123(6). PMID: 32694695    Free PMC article.
Review.
PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy.
Yi Qin, Lili Jiang, +11 authors, Meijuan Huang.
Sci Rep, 2020 Oct 02; 10(1). PMID: 32999345    Free PMC article.
Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents.
Mariona Riudavets, Joaquin Mosquera, +9 authors, Margarita Majem.
Front Oncol, 2020 Oct 06; 10. PMID: 33014837    Free PMC article.
ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC.
Yao Chen, Xiaobin Li, +4 authors, Yina Wang.
Front Oncol, 2020 Oct 06; 10. PMID: 33014846    Free PMC article.
[Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].
Qiaoxi Qin, Jiajin Wang, Hong Wang.
Zhongguo Fei Ai Za Zhi, 2020 Aug 06; 23(9). PMID: 32752580    Free PMC article.
Systematic Review.
Immune checkpoint inhibitor-related dermatologic adverse events.
Amaris N Geisler, Gregory S Phillips, +5 authors, Mario E Lacouture.
J Am Acad Dermatol, 2020 May 27; 83(5). PMID: 32454097    Free PMC article.
Review.
Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer.
Chaoyue Su, Hui Wang, +7 authors, Jianye Zhang.
Front Oncol, 2020 Oct 20; 10. PMID: 33072580    Free PMC article.
Review.
Combined Methylome and Transcriptome Analyses Reveals Potential Therapeutic Targets for EGFR Wild Type Lung Cancers with Low PD-L1 Expression.
Weilei Hu, Guosheng Wang, Lonny B Yarmus, Yuan Wan.
Cancers (Basel), 2020 Sep 10; 12(9). PMID: 32899191    Free PMC article.
Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective.
Wen-Jia Shi, Wei Zhao.
Chin Med J (Engl), 2020 Sep 23; 133(20). PMID: 32960841    Free PMC article.
Review.
The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients: A systematic review and meta-analysis.
Dongmei Xu, Hongmei Liu, +7 authors, Yuan Tian.
Medicine (Baltimore), 2020 Oct 09; 99(41). PMID: 33031304    Free PMC article.
Systematic Review.
The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients: A systematic review and meta-analysis.
Mingkai Li, Linlin Huang, +7 authors, Fuli Mi.
Medicine (Baltimore), 2020 Oct 22; 99(42). PMID: 33080690    Free PMC article.
Systematic Review.
Clinical Investigation of the Efficacy and Safety of Anlotinib with Immunotherapy in Advanced Non-Small Cell Lung Cancer as Third-Line Therapy: A Retrospective Study.
Shengjie Yang, Wenjie Zhang, Qing Chen, Qisen Guo.
Cancer Manag Res, 2020 Oct 30; 12. PMID: 33116888    Free PMC article.
First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress.
Zhangfeng Huang, Wenhao Su, +6 authors, Wenjie Jiao.
Front Pharmacol, 2020 Oct 30; 11. PMID: 33117170    Free PMC article.
Review.
Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis.
Vittorio Gebbia, Marco Maria Aiello, +12 authors, Paolo Vigneri.
Ecancermedicalscience, 2020 Nov 05; 14. PMID: 33144881    Free PMC article.
Future of immune checkpoint inhibitors: focus on tumor immune microenvironment.
Yunlong Jia, Lihua Liu, Baoen Shan.
Ann Transl Med, 2020 Nov 05; 8(17). PMID: 33145314    Free PMC article.
Review.
Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer.
Wenxian Wang, Zhangzhou Huang, +10 authors, Zhengbo Song.
Front Oncol, 2020 Nov 10; 10. PMID: 33163403    Free PMC article.
Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know.
Simone Camelliti, Valentino Le Noci, +8 authors, Michele Sommariva.
J Exp Clin Cancer Res, 2020 Nov 11; 39(1). PMID: 33168050    Free PMC article.
Review.
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma.
Beatrice Casadei, Lisa Argnani, +9 authors, Pier Luigi Zinzani.
Cancer Med, 2020 Sep 04; 9(21). PMID: 32881376    Free PMC article.
Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis.
Hongmei Liu, Dongmei Xu, +4 authors, Yuan Tian.
Front Oncol, 2020 Nov 17; 10. PMID: 33194659    Free PMC article.
Systematic Review.
A pathological complete response to neoadjuvant chemotherapy and immunotherapy in a non-small cell lung cancer patient.
Pengqiang Gao, Hao Chen, +7 authors, Chun Chen.
Transl Lung Cancer Res, 2020 Nov 20; 9(5). PMID: 33209635    Free PMC article.
CDK5 Inhibition Abrogates TNBC Stem-Cell Property and Enhances Anti-PD-1 Therapy.
Yuncheng Bei, Nan Cheng, +13 authors, Pingping Shen.
Adv Sci (Weinh), 2020 Nov 27; 7(22). PMID: 33240752    Free PMC article.
'Genotype/immunotype' correlations in resected NSCLC.
P K Paik, M D Hellmann.
Ann Oncol, 2017 Jan 01; 28(1). PMID: 28039156    Free PMC article.
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
R Hui, E B Garon, +15 authors, N A Rizvi.
Ann Oncol, 2017 Feb 09; 28(4). PMID: 28168303    Free PMC article.
Highly Cited.
Progress in the Management of Malignant Pleural Mesothelioma in 2017.
Amanda J McCambridge, Andrea Napolitano, +9 authors, Tobias Peikert.
J Thorac Oncol, 2018 Mar 11; 13(5). PMID: 29524617    Free PMC article.
Review.
The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study.
T Karantanos, S Karanika, B Seth, G Gignac.
Clin Transl Oncol, 2018 Jun 28; 21(2). PMID: 29948974
Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer.
W Jeffrey Petty, James J Urbanic, +10 authors, A William Blackstock.
Int J Radiat Oncol Biol Phys, 2018 Jul 14; 102(3). PMID: 30003996    Free PMC article.
Predictive potential and need for standardization of PD-L1 immunohistochemistry.
Spasenija Savic Prince, Lukas Bubendorf.
Virchows Arch, 2018 Sep 03; 474(4). PMID: 30173280
Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer.
Emmett V Schmidt.
Semin Immunopathol, 2018 Oct 31; 41(1). PMID: 30374524    Free PMC article.
Review.
Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
Sung Won Lim, Myung-Ju Ahn.
Korean J Intern Med, 2019 Jan 08; 34(1). PMID: 30612418    Free PMC article.
Review.
Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.
J Corral, M Majem, +7 authors, M P López Criado.
Clin Transl Oncol, 2019 Feb 17; 21(9). PMID: 30771085
PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives.
Yumeng Wang, Guiling Li.
Front Med, 2019 Mar 04; 13(4). PMID: 30826965
Review.
Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer.
Farhan S Cyprian, Saghir Akhtar, Zoran Gatalica, Semir Vranic.
Bosn J Basic Med Sci, 2019 Mar 28; 19(3). PMID: 30915922    Free PMC article.
Highly Cited. Review.
Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials.
Alberto Carretero-González, David Lora, +4 authors, Guillermo de Velasco.
Oncotarget, 2019 May 31; 10(35). PMID: 31143375    Free PMC article.
The overall safety evaluation of programmed cell death/programmed cell death ligand 1 (PD-1/PD-L1) treatment for lung cancer patients: An updated systematic review and meta-analysis.
Heli Shang, Zewen Zhang, +7 authors, Yuan Tian.
Medicine (Baltimore), 2019 Jul 28; 98(30). PMID: 31348245    Free PMC article.
Systematic Review.
Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression.
Elly Marcq, Jonas Rm Van Audenaerde, +6 authors, Evelien Lj Smits.
Int J Mol Sci, 2019 Aug 29; 20(17). PMID: 31455014    Free PMC article.
Intestinal transport mechanism and in vivo anticancer efficacy of a solid oral formulation incorporating an ion-pairing complex of pemetrexed with deoxycholic acid derivative.
Rudra Pangeni, Saurav Kumar Jha, +5 authors, Jin Woo Park.
Int J Nanomedicine, 2019 Sep 10; 14. PMID: 31496690    Free PMC article.
Synthetic lethality as an engine for cancer drug target discovery.
Alan Huang, Levi A Garraway, Alan Ashworth, Barbara Weber.
Nat Rev Drug Discov, 2019 Nov 13; 19(1). PMID: 31712683
Review.
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Hossein Borghaei, Corey J Langer, +10 authors, Shirish M Gadgeel.
Cancer, 2020 Sep 12; 126(22). PMID: 32914866    Free PMC article.
Efficacy and safety of combination PD-1/PD-L1 checkpoint inhibitors for malignant solid tumours: A systematic review.
Qigu Yao, Lihu Gu, +2 authors, Hongcui Cao.
J Cell Mol Med, 2020 Oct 21; 24(22). PMID: 33078904    Free PMC article.
Systematic Review.
Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.
Chia-Sing Lu, Ching-Wen Lin, +10 authors, Pan-Chyr Yang.
J Immunother Cancer, 2020 Nov 28; 8(2). PMID: 33243934    Free PMC article.
Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy.
Megan M Tu, Hany A Abdel-Hafiz, +10 authors, Dan Theodorescu.
Commun Biol, 2020 Nov 29; 3(1). PMID: 33247183    Free PMC article.
Radiation and immunotherapy: emerging mechanisms of synergy.
William G Breen, Konstantinos Leventakos, Haidong Dong, Kenneth W Merrell.
J Thorac Dis, 2020 Dec 08; 12(11). PMID: 33282406    Free PMC article.
Review.

;. PMID: 33323935
Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer.
John Conibear, AstraZeneca UK Limited.
Br J Cancer, 2020 Dec 10; 123(Suppl 1). PMID: 33293671    Free PMC article.
Review.
Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis.
Sibo Tian, Jeffrey M Switchenko, +9 authors, Kristin A Higgins.
Int J Radiat Oncol Biol Phys, 2020 Jan 27; 108(1). PMID: 31982496    Free PMC article.
The Advanced Practice Provider Perspective: Treating Patients With Immuno-Oncology Combination Therapy Across Tumor Types.
Brianna Hoffner, Renae Vaughn, Maureen Reed, Melinda S Weber.
J Adv Pract Oncol, 2019 May 01; 10(4). PMID: 33343985    Free PMC article.
Review.
The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors.
Marcin Nicoś, Paweł Krawczyk, Nicola Crosetto, Janusz Milanowski.
Front Oncol, 2020 Dec 22; 10. PMID: 33344229    Free PMC article.
Review.
Regulation and Function of the PD-L1 Checkpoint.
Chong Sun, Riccardo Mezzadra, Ton N Schumacher.
Immunity, 2018 Mar 22; 48(3). PMID: 29562194    Free PMC article.
Highly Cited. Review.
Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review.
Xiaolin Liu, Xiuju Liang, +2 authors, Jun Wang.
Front Oncol, 2020 Dec 29; 10. PMID: 33365266    Free PMC article.
Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC.
Pierre-Olivier Gaudreau, Marcelo V Negrao, +35 authors, Don L Gibbons.
J Thorac Oncol, 2020 Oct 24; 16(1). PMID: 33096269    Free PMC article.
Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma-a long-term follow-up single center experience.
Malte Roerden, Martin Sökler, +3 authors, Juliane S Walz.
Ann Hematol, 2020 Jan 04; 99(2). PMID: 31897675
Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
Yuan Tian, Aiqin Gao, +5 authors, Yuping Sun.
Front Immunol, 2021 Jan 05; 11. PMID: 33391266    Free PMC article.
Systematic Review.
[Systemic treatment of bladder cancer].
Alexander Tamalunas, Gerald B Schulz, +3 authors, Jozefina Casuscelli.
Urologe A, 2021 Jan 06; 60(2). PMID: 33398384
Review.
Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis.
Han Li, Jinsheng Xu, +3 authors, Jingjing Jin.
Invest New Drugs, 2021 Jan 08; 39(3). PMID: 33409896    Free PMC article.
Systematic Review.
Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
Michael Zhang, Adrian J Rodrigues, +11 authors, Gordon Li.
J Neurooncol, 2021 Jan 09; 152(1). PMID: 33415659    Free PMC article.
Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers.
V Chung, F J Kos, +8 authors, D J Diamond.
Clin Transl Oncol, 2018 Aug 11; 21(3). PMID: 30094792    Free PMC article.
Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy.
Wei Li, Anghui Peng, +4 authors, Min Cui.
Front Immunol, 2021 Jan 08; 11. PMID: 33408716    Free PMC article.
Review.
[Research Progress in the Treatment of Brain Metastases 
from Non-small Cell Lung Cancer].
Xue Han, Hongmei Li.
Zhongguo Fei Ai Za Zhi, 2020 Dec 29; 23(12). PMID: 33357316    Free PMC article.
Review.
Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis.
Qingyuan Huang, Yuzhen Zheng, +3 authors, Haiquan Chen.
J Cancer, 2021 Jan 15; 12(4). PMID: 33442411    Free PMC article.
Evolution of Lung Cancer in the Context of Immunotherapy.
Sheng Yu, Ruilin Wang, +10 authors, Yufeng Wu.
Clin Med Insights Oncol, 2021 Jan 16; 14. PMID: 33447125    Free PMC article.
Review.
Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer.
Eugene Muchnik, Kah Poh Loh, +4 authors, Ronald J Maggiore.
J Am Geriatr Soc, 2019 Jan 31; 67(5). PMID: 30698276    Free PMC article.
Highly Cited.
Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients.
S I Rothschild, R Nachbur, +2 authors, M Pless.
ESMO Open, 2021 Jan 11; 6(1). PMID: 33422767    Free PMC article.
The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3.
Elly Marcq, Jonas R M Van Audenaerde, +5 authors, Evelien L J Smits.
Cancers (Basel), 2021 Jan 21; 13(2). PMID: 33466653    Free PMC article.
Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades.
Jun-Yan Li, Yu-Pei Chen, +2 authors, Jun Ma.
Mol Cancer, 2021 Feb 06; 20(1). PMID: 33541368    Free PMC article.
Review.
Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer.
Marina Martinez, Soyeon Kim, +5 authors, Edmund Moon.
Oncoimmunology, 2021 Feb 05; 10(1). PMID: 33537176    Free PMC article.
Incidence risk of PD-1/PD-L1-related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials.
Zhi-Qiang Tong, Dong-Yuan Wu, Duo Liu, Mei Dong.
Eur J Clin Pharmacol, 2021 Feb 11; 77(8). PMID: 33564898
Systematic Review.
Immune checkpoint inhibition in syngeneic mouse cancer models by a silicasome nanocarrier delivering a GSK3 inhibitor.
Sean D Allen, Xiangsheng Liu, +4 authors, Huan Meng.
Biomaterials, 2021 Jan 11; 269. PMID: 33422940    Free PMC article.
Smoking history and the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
Da-Li Chen, Qing-Yuan Li, Qun-You Tan.
J Thorac Dis, 2021 Feb 12; 13(1). PMID: 33569202    Free PMC article.
Induction treatment in patients with stage III non-small cell lung cancer.
Ramón Palmero, Noelia Vilariño, Arturo Navarro-Martín, Ernest Nadal.
Transl Lung Cancer Res, 2021 Feb 12; 10(1). PMID: 33569335    Free PMC article.
Review.
Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer.
Caroline Huynh, Logan A Walsh, Jonathan D Spicer.
Transl Lung Cancer Res, 2021 Feb 12; 10(1). PMID: 33569337    Free PMC article.
Review.
Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers.
Guihua Wang, Qin Chai, +6 authors, Lin Wu.
Front Immunol, 2021 Feb 16; 11. PMID: 33584678    Free PMC article.
Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials.
Xiang Li, Shi Yan, +7 authors, Nan Wu.
Front Oncol, 2021 Feb 16; 10. PMID: 33585195    Free PMC article.
Systematic Review.
Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1.
Anna Makowska, Selina Meier, +3 authors, Udo Kontny.
Cancer Immunol Immunother, 2020 Aug 02; 70(2). PMID: 32737537    Free PMC article.
Xanthatin synergizes with cisplatin to suppress homologous recombination through JAK2/STAT4/BARD1 axis in human NSCLC cells.
Jian Zhang, Sheng Yang, +2 authors, Yuan Gao.
J Cell Mol Med, 2021 Jan 14; 25(3). PMID: 33439503    Free PMC article.
Human drug efflux transporter ABCC5 confers acquired resistance to pemetrexed in breast cancer.
Jihui Chen, Zhipeng Wang, +9 authors, Yan Liu.
Cancer Cell Int, 2021 Feb 27; 21(1). PMID: 33632224    Free PMC article.
In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
Daniel J Rubins, Xiangjun Meng, +16 authors, Jeffrey L Evelhoch.
Mol Imaging Biol, 2020 Oct 25; 23(2). PMID: 33098025
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer.
Jingjing Qu, Quanhui Mei, +4 authors, Jianying Zhou.
Ther Adv Med Oncol, 2021 Mar 02; 13. PMID: 33643442    Free PMC article.
Review.
Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Xiaolin Yu, Xiaomei Zhang, +2 authors, Yanxia Zhang.
Front Med (Lausanne), 2021 Mar 05; 8. PMID: 33659263    Free PMC article.
Systematic Review.
COMMD1, from the Repair of DNA Double Strand Breaks, to a Novel Anti-Cancer Therapeutic Target.
Amila Suraweera, Pascal H G Duijf, +5 authors, Derek J Richard.
Cancers (Basel), 2021 Mar 07; 13(4). PMID: 33669398    Free PMC article.
Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.
Alberto Carretero-González, Irene Otero, +3 authors, Guillermo de Velasco.
Oncoimmunology, 2021 Mar 09; 10(1). PMID: 33680572    Free PMC article.
Systematic Review.
Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation.
Yixuan Zhou, Ingmar Niels Bastian, +30 authors, Shabnam Shalapour.
Proc Natl Acad Sci U S A, 2021 Feb 20; 118(8). PMID: 33602823    Free PMC article.
Novel risk scoring system for immune checkpoint inhibitors treatment in non-small cell lung cancer.
Chuling Li, Meiqi Shi, +9 authors, Yong Song.
Transl Lung Cancer Res, 2021 Mar 16; 10(2). PMID: 33718021    Free PMC article.
A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer.
Yunes Panahi, Amir Hossein Mohammadzadeh, +3 authors, Amirhossein Sahebkar.
Adv Exp Med Biol, 2021 Mar 17; 1286. PMID: 33725344
Review.
Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery.
Min Ho Lee, Kyung-Rae Cho, +10 authors, Jung-Il Lee.
J Korean Neurosurg Soc, 2020 Dec 04; 64(2). PMID: 33267531    Free PMC article.
Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Jun Shao, Chengdi Wang, +3 authors, Weimin Li.
Biosci Rep, 2020 Apr 22; 40(5). PMID: 32315071    Free PMC article.
Systematic Review.
A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).
Xianbin Kong, Peng Lu, +8 authors, Jingyan Meng.
Mol Med Rep, 2021 Mar 25; 23(5). PMID: 33760188    Free PMC article.
Review.
Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma.
Nobuki Furubayashi, Yoshifumi Hori, +7 authors, Motonobu Nakamura.
Mol Clin Oncol, 2021 Mar 27; 14(5). PMID: 33767860    Free PMC article.
Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis.
Angelo Borsarelli Carvalho Brito, Marcos Pedro Guedes Camandaroba, Vladmir Cláudio Cordeiro de Lima.
Thorac Cancer, 2021 Feb 16; 12(7). PMID: 33586297    Free PMC article.
Systematic Review.
Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials.
Ramez N Eskander, Matthew A Powell.
Ther Adv Med Oncol, 2021 Apr 03; 13. PMID: 33796152    Free PMC article.
Review.
Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer.
Xue Wang, Xiaomin Niu, +2 authors, Zhiwei Chen.
Front Oncol, 2021 Apr 06; 11. PMID: 33816241    Free PMC article.
Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy.
Quynh Thu Le, A Dimitrios Colevas, +9 authors, Shakun Malik.
J Natl Cancer Inst, 2019 Mar 27; 111(7). PMID: 30912808    Free PMC article.
Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer.
W Yao, X Zhao, +7 authors, S Jiao.
ESMO Open, 2021 Mar 30; 6(2). PMID: 33780892    Free PMC article.
Prognostic Nutritional Index identifies risk of early progression and survival outcomes in Advanced Non-small Cell Lung Cancer patients treated with PD-1 inhibitors.
Na Liu, Aimin Jiang, +8 authors, Yu Yao.
J Cancer, 2021 Apr 16; 12(10). PMID: 33854596    Free PMC article.
Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC.
Xinran Ma, Lawrence Bellomo, +8 authors, Ariel Bulua Bourla.
Adv Ther, 2021 Mar 07; 38(4). PMID: 33674928    Free PMC article.
Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives.
Rafieh Bagherifar, Seyed Hossein Kiaie, +5 authors, Yousef Javadzadeh.
J Nanobiotechnology, 2021 Apr 19; 19(1). PMID: 33865432    Free PMC article.
Review.
Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy.
Jing Liu, Zhihao Zhao, +7 authors, Youqing Shen.
Nat Commun, 2021 Apr 25; 12(1). PMID: 33893275    Free PMC article.
The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Y Yang, H Luo, X L Zheng, H Ge.
Clin Transl Oncol, 2020 Nov 20; 23(6). PMID: 33211281
Systematic Review.
Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices.
Vamsidhar Velcheti, Xiaohan Hu, Bilal Piperdi, Thomas Burke.
Sci Rep, 2021 Apr 30; 11(1). PMID: 33911121    Free PMC article.
Immune-related adverse events of checkpoint inhibitors.
Manuel Ramos-Casals, Julie R Brahmer, +7 authors, Maria E Suárez-Almazor.
Nat Rev Dis Primers, 2020 May 10; 6(1). PMID: 32382051
Review.
Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study.
Hui Li, Shukui Qin, +8 authors, Jianjun Zou.
Drug Des Devel Ther, 2021 May 13; 15. PMID: 33976538    Free PMC article.
Strategies for the Construction of Mouse Models With Humanized Immune System and Evaluation of Tumor Immune Checkpoint Inhibitor Therapy.
Wenwen Guo, Caiqin Zhang, +2 authors, Changhong Shi.
Front Oncol, 2021 May 18; 11. PMID: 33996603    Free PMC article.
Review.
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
Mark M Awad, Giulia C Leonardi, +16 authors, Rebecca S Heist.
Lung Cancer, 2019 Jun 16; 133. PMID: 31200835    Free PMC article.
A nomogram for predicting overall survival in patients with resected non-small cell lung cancer treated with chemotherapy.
Yuan Zeng, Nicholas Mayne, +6 authors, written on behalf of the AME Thoracic Surgery Collaborative Group.
Transl Lung Cancer Res, 2021 May 21; 10(4). PMID: 34012785    Free PMC article.
Population-level changes in outcomes and Medicare cost following the introduction of new cancer therapies.
Bora Youn, Ira B Wilson, +2 authors, Issa J Dahabreh.
Health Serv Res, 2021 Mar 09; 56(3). PMID: 33682120    Free PMC article.
Immune subgroup analysis for non-small cell lung cancer may be a good choice for evaluating therapeutic efficacy and prognosis.
Yuan Tian, Jingnan Wang, +2 authors, Yuping Sun.
Aging (Albany NY), 2021 May 12; 13(9). PMID: 33973529    Free PMC article.
Miliary pattern on chest imaging as a presentation of EGFR-negative primary lung adenocarcinoma.
Seth A Hoffman, Scott Manski, Janaki Deepak.
BMJ Case Rep, 2019 Jun 04; 12(5). PMID: 31151972    Free PMC article.
Prognostic implications of PD-L1 expression in patients with angiosarcoma.
Jii Bum Lee, Beung-Chul Ahn, +5 authors, Hyo Song Kim.
Future Sci OA, 2021 May 29; 7(5). PMID: 34046193    Free PMC article.
Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review.
Tao Ouyang, Yanyan Cao, +7 authors, Chuansheng Zheng.
Front Oncol, 2021 May 29; 11. PMID: 34046338    Free PMC article.
Systematic Review.
Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer.
Yuzhong Chen, Shaodi Wen, +5 authors, Bo Shen.
Front Immunol, 2021 Jun 01; 12. PMID: 34054853    Free PMC article.
Practical Issues in the Use of Atezolizumab for Patients with Non-Small Cell Lung Cancer: Case Reports and Literature Review.
Manuel Cobo, Delvys Rodríguez-Abreu, +2 authors, Jorge G González.
Oncol Ther, 2021 Feb 15; 9(1). PMID: 33582978    Free PMC article.
Review.
Immune Checkpoint Inhibitors in Prostate Cancer.
Shobi Venkatachalam, Taylor R McFarland, Neeraj Agarwal, Umang Swami.
Cancers (Basel), 2021 Jun 03; 13(9). PMID: 34063238    Free PMC article.
Review.
Testing EGFR with Idylla on Cytological Specimens of Lung Cancer: A Review.
Alessandro Caputo, Angela D'Ardia, +4 authors, Antonio D'Antonio.
Int J Mol Sci, 2021 Jun 03; 22(9). PMID: 34063720    Free PMC article.
Review.
PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects.
Enrico Munari, Francesca R Mariotti, +9 authors, Lorenzo Moretta.
Int J Mol Sci, 2021 Jun 03; 22(10). PMID: 34066087    Free PMC article.
Review.
Generation of TIM3 inhibitory single-domain antibodies to boost the antitumor activity of chimeric antigen receptor T cells.
Liu Yang, Xin Chen, +11 authors, Mingqian Feng.
Oncol Lett, 2021 Jun 04; 22(1). PMID: 34079595    Free PMC article.
Development of Immunotherapy Combination Strategies in Cancer.
Timothy A Yap, Eileen E Parkes, +3 authors, Hussein A Tawbi.
Cancer Discov, 2021 Apr 04; 11(6). PMID: 33811048    Free PMC article.
Review.
Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis.
Lei Sheng, Jing Gao, +5 authors, Lian Liu.
Ther Adv Med Oncol, 2021 Jun 10; 13. PMID: 34104227    Free PMC article.
Review.
Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis.
Yuan Tian, Alan Huang, +4 authors, Yuping Sun.
Front Oncol, 2021 Jun 11; 11. PMID: 34109117    Free PMC article.
Systematic Review.
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies.
Kenneth K W To, Winnie Fong, William C S Cho.
Front Oncol, 2021 Jun 12; 11. PMID: 34113560    Free PMC article.
Review.
A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study.
John M Varlotto, Zhuoxin Sun, +12 authors, Nathan A Pennell.
Oncologist, 2021 Feb 18; 26(6). PMID: 33594771    Free PMC article.
Review.
Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report.
Xiaomin Niu, Yingjia Sun, +4 authors, Shun Lu.
Front Oncol, 2021 Jun 29; 11. PMID: 34178624    Free PMC article.
Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States.
Marion Ferreira, Thomas Secher, Nathalie Heuze-Vourc'H, Karen L Reckamp.
Pharmaceutics, 2021 Jul 03; 13(6). PMID: 34205484    Free PMC article.
Review.
Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Fausto Petrelli, Anna Maria Morelli, +2 authors, Cinzia Solinas.
Target Oncol, 2021 Jul 06; 16(5). PMID: 34224061    Free PMC article.
Systematic Review.
The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis.
Sihan Li, Hongwei Zhang, +2 authors, Jun Dang.
Front Oncol, 2021 Jul 13; 11. PMID: 34249764    Free PMC article.
Systematic Review.
Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer.
Mizuki Nishino, Fangxin Hong, +2 authors, Mark M Awad.
JCO Precis Oncol, 2021 Jul 13; 5. PMID: 34250409    Free PMC article.
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.
Martin Reck, Delvys Rodríguez-Abreu, +16 authors, Julie R Brahmer.
J Clin Oncol, 2021 Apr 20; 39(21). PMID: 33872070    Free PMC article.
Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study.
Myeong Geun Choi, Chang-Min Choi, +5 authors, Jae Cheol Lee.
Transl Lung Cancer Res, 2021 Jul 24; 10(6). PMID: 34295661    Free PMC article.
A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer.
Malcolm D Mattes, Timothy D Eubank, +4 authors, Patrick C Ma.
Clin Lung Cancer, 2021 Feb 21; 22(4). PMID: 33608212    Free PMC article.
The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
Xiaohua Li, Yuntao Wang, +3 authors, Yifeng Bai.
Front Immunol, 2021 Jul 27; 12. PMID: 34305884    Free PMC article.
The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study.
Jason C Hsu, Phung-Anh Nguyen, +18 authors, Christine Y Lu.
Front Oncol, 2021 Jul 27; 11. PMID: 34307141    Free PMC article.
A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression.
Roy Herbst, Jacek Jassem, +5 authors, Filippo De Marinis.
Front Oncol, 2021 Jul 27; 11. PMID: 34307144    Free PMC article.
Review.
Prognosis of Non-small-cell Lung Cancer Patients With Lipid Metabolism Pathway Alternations to Immunotherapy.
Tianli Cheng, Jing Zhang, +2 authors, Xiaoping Wen.
Front Genet, 2021 Aug 03; 12. PMID: 34335679    Free PMC article.
Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients.
Stefano Bracci, Miriam Dolciami, +5 authors, Paolo Ricci.
Radiol Med, 2021 Aug 11; 126(11). PMID: 34373989    Free PMC article.
Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study.
Hidehito Horinouchi, Naoyuki Nogami, +10 authors, Takayasu Kurata.
Cancer Sci, 2021 May 27; 112(8). PMID: 34036692    Free PMC article.
Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer.
Ying Cheng, Hui Li, +3 authors, Shuang Zhang.
Chin Med J (Engl), 2021 Jun 17; 134(15). PMID: 34133356    Free PMC article.
Review.
Efficacy and safety of pembrolizumab/carrelizumab, alone or in combination with chemotherapy in treatment of patients with non-small cell lung cancer: A protocol for evidence-based systematic review and Bayesian network meta-analysis.
Xiaofei Zhang, Hui Qian, Xiangkun Qu, Yalin Jiang.
Medicine (Baltimore), 2021 Aug 17; 100(29). PMID: 34398032    Free PMC article.
Systematic Review.
The detection value of PD-L1 expression in biopsy specimens and surgical resection specimens in non-small cell lung cancer: a meta-analysis.
Yang Wang, Junqi Wu, +2 authors, Chang Chen.
J Thorac Dis, 2021 Aug 24; 13(7). PMID: 34422357    Free PMC article.
Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials.
Yang Ge, Huiyun Zhang, Nathaniel Weygant, Jiannan Yao.
Front Pharmacol, 2021 Aug 28; 12. PMID: 34447305    Free PMC article.
Natural Killer Cells and Dendritic Cells: Expanding Clinical Relevance in the Non-Small Cell Lung Cancer (NSCLC) Tumor Microenvironment.
Pankaj Ahluwalia, Meenakshi Ahluwalia, +4 authors, Ravindra Kolhe.
Cancers (Basel), 2021 Aug 28; 13(16). PMID: 34439191    Free PMC article.
Review.
The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
Chengdi Wang, Jingwei Li, +5 authors, Yalun Li.
BMC Cancer, 2021 Aug 30; 21(1). PMID: 34454455    Free PMC article.
Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Hao Zeng, Wei-Wei Huang, +5 authors, Wei-Min Li.
Front Oncol, 2021 Aug 31; 11. PMID: 34458139    Free PMC article.
Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges.
Chu-Ling Li, Yong Song.
Chin Med J (Engl), 2021 Aug 04; 134(16). PMID: 34343148    Free PMC article.
Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC).
Ziyi Xu, Teng Li, +3 authors, Junling Li.
Thorac Cancer, 2021 Jul 17; 12(17). PMID: 34268872    Free PMC article.
Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Qian Xu, Xue Zhang, +7 authors, Lian Liu.
Front Immunol, 2021 Sep 07; 12. PMID: 34484242    Free PMC article.
Systematic Review.
High linear energy transfer carbon-ion irradiation upregulates PD-L1 expression more significantly than X-rays in human osteosarcoma U2OS cells.
Tiara Bunga Mayang Permata, Hiro Sato, +13 authors, Atsushi Shibata.
J Radiat Res, 2021 Jul 02; 62(5). PMID: 34196706    Free PMC article.
Combination strategies to maximize the benefits of cancer immunotherapy.
Shaoming Zhu, Tian Zhang, +5 authors, Chong-Xian Pan.
J Hematol Oncol, 2021 Sep 29; 14(1). PMID: 34579759    Free PMC article.
Review.
Clinical management of immune-related adverse events following immunotherapy treatment in patients with non-small cell lung cancer.
Hannah Elizabeth Green, Jorge Nieva.
J Investig Med, 2021 Jun 16; 69(7). PMID: 34127515    Free PMC article.
Review.
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis.
Alessandro Di Federico, Andrea De Giglio, +3 authors, Andrea Ardizzoni.
JTO Clin Res Rep, 2021 Oct 01; 2(9). PMID: 34590054    Free PMC article.
Transcriptome Analyses Identify a Metabolic Gene Signature Indicative of Antitumor Immunosuppression of EGFR Wild Type Lung Cancers With Low PD-L1 Expression.
Min Wang, Jie Zhu, Fang Zhao, Jiani Xiao.
Front Oncol, 2021 Oct 02; 11. PMID: 34595103    Free PMC article.
Digital pathology and artificial intelligence in translational medicine and clinical practice.
Vipul Baxi, Robin Edwards, Michael Montalto, Saurabh Saha.
Mod Pathol, 2021 Oct 07; 35(1). PMID: 34611303    Free PMC article.
Review.
Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non-small cell lung cancer.
Li-Yue Sun, Wen-Jian Cen, +8 authors, Zi-Ming Du.
Cancer Med, 2021 Sep 02; 10(19). PMID: 34469045    Free PMC article.
Immune Checkpoint Inhibitor-Associated Tumor Lysis Syndrome: A Real-World Pharmacovigilance Study.
Li Wang, Xiaolin Li, +3 authors, Jingli Duan.
Front Pharmacol, 2021 Oct 12; 12. PMID: 34630077    Free PMC article.
Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations.
Jiatao Liao, Chang Liu, +8 authors, Jialei Wang.
Front Oncol, 2021 Oct 19; 11. PMID: 34660317    Free PMC article.
[Peripheral Blood Inflammation Indicators as Predictive Indicators in 
Immunotherapy of Advanced Non-small Cell Lung Cancer].
Jingwei Xia, Yuzhong Chen, +2 authors, Bo Shen.
Zhongguo Fei Ai Za Zhi, 2021 Sep 16; 24(9). PMID: 34521188    Free PMC article.
[Effects of neoadjuvant chemoradiotherapy on infiltrating immune cells in the tumor microenvironment of rectal cancer].
Q Yang, C Zhou, +4 authors, J Ma.
Nan Fang Yi Ke Da Xue Xue Bao, 2021 Sep 23; 41(8). PMID: 34549721    Free PMC article.
Improved Immunotherapy Efficacy by Vascular Modulation.
Emma L Newport, Ana Rita Pedrosa, +2 authors, José M Muñoz-Félix.
Cancers (Basel), 2021 Oct 24; 13(20). PMID: 34680355    Free PMC article.
Review.
Research Progress and Challenges in the Treatment of Central Nervous System Metastasis of Non-Small Cell Lung Cancer.
Bin Wang, Hanfei Guo, +3 authors, Gang Zhao.
Cells, 2021 Oct 24; 10(10). PMID: 34685600    Free PMC article.
Review.
Response to toripalimab combined with radiotherapy in advanced non-small cell lung cancer-not otherwise specified: A case report.
Yonglong Jin, Wenjing Xiao, +3 authors, Xiguang Liu.
Medicine (Baltimore), 2021 Oct 23; 100(42). PMID: 34678907    Free PMC article.
Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: A systematic review and network meta-analysis.
Tzu-Rong Peng, Hung-Hong Lin, Fang-Pei Tsai, Ta-Wei Wu.
Thorac Cancer, 2021 Sep 22; 12(21). PMID: 34545685    Free PMC article.
Systematic Review.
Prognostic implication of erector spinae muscles in non-small-cell lung cancer patients treated with immuno-oncology combinatorial chemotherapy.
Taisuke Araki, Yoshiaki Kitaguchi, +5 authors, Masayuki Hanaoka.
Thorac Cancer, 2021 Oct 03; 12(21). PMID: 34599854    Free PMC article.
Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials.
Weidong Zhang, Jingjing Gu, Chunming Bian, Guanhong Huang.
Front Pharmacol, 2021 Nov 12; 12. PMID: 34759817    Free PMC article.
Review.
Metabolism in tumor microenvironment: Implications for cancer immunotherapy.
Rongchen Shi, Yi-Quan Tang, Hongming Miao.
MedComm (2020), 2020 Jun 03; 1(1). PMID: 34766109    Free PMC article.
Review.
The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries.
Maria V Deligiorgi, Sofia Sagredou, Lampros Vakkas, Dimitrios T Trafalis.
Cancers (Basel), 2021 Nov 14; 13(21). PMID: 34771441    Free PMC article.
Review.
The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection.
Jinpeng Shi, Jiayu Li, +13 authors, Caicun Zhou.
Transl Lung Cancer Res, 2021 Dec 04; 10(10). PMID: 34858782    Free PMC article.
A Novel Approach Using FDG-PET/CT-Based Radiomics to Assess Tumor Immune Phenotypes in Patients With Non-Small Cell Lung Cancer.
Jianyuan Zhou, Sijuan Zou, +3 authors, Xiaohua Zhu.
Front Oncol, 2021 Dec 07; 11. PMID: 34868999    Free PMC article.
Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China.
Anwen Xiong, Jiali Wang, Caicun Zhou.
Front Oncol, 2021 Dec 14; 11. PMID: 34900707    Free PMC article.
Review.
Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies.
Ellen Cusano, Chelsea Wong, +7 authors, Doreen Ezeife.
Curr Oncol, 2021 Dec 14; 28(6). PMID: 34898590    Free PMC article.
A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yi-Dan Yan, Jiu-Jie Cui, +4 authors, Hou-Wen Lin.
Front Immunol, 2021 Dec 21; 12. PMID: 34925331    Free PMC article.
Systematic Review.
Genetic Alteration Profiling of Chinese Lung Adenocarcinoma and Its Effect on Targeted Therapy Efficacy.
Jie Liu, Wang-Yang Xu, +2 authors, Chun Li.
Front Oncol, 2022 Jan 01; 11. PMID: 34970478    Free PMC article.
Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.
Yuan Cheng, Tao Zhang, Qing Xu.
MedComm (2020), 2022 Jan 04; 2(4). PMID: 34977873    Free PMC article.
Review.
The prospect of immunotherapy combined with chemotherapy in patients with advanced non-small cell lung cancer: a narrative review.
Xiangu Ning, Yang Yu, +9 authors, Hushan Zhang.
Ann Transl Med, 2022 Jan 07; 9(22). PMID: 34988212    Free PMC article.
Review.
A case of successful pembrolizumab monotherapy in a patient with advanced lung adenocarcinoma: Use of multiple biomarkers in combination for clinical practice.
Hanfei Guo, Lei Qian, +4 authors, Jiuwei Cui.
Open Med (Wars), 2022 Jan 08; 17(1). PMID: 34993345    Free PMC article.
What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Qingyi Wang, Bin Xie, +4 authors, Wenxiang Wang.
Front Immunol, 2022 Jan 11; 12. PMID: 35003090    Free PMC article.
Review.
Pembrolizumab provides long-term survival benefits in advanced non-small cell lung cancer: The 5-year outcomes of the KEYNOTE-024 trial.
Fengtan Li, Xifeng Dong.
Thorac Cancer, 2021 Oct 14; 12(23). PMID: 34643064    Free PMC article.
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.
Ming Yi, Xiaoli Zheng, +3 authors, Kongming Wu.
Mol Cancer, 2022 Jan 23; 21(1). PMID: 35062949    Free PMC article.
Review.
Efficacy and safety of anti-PD-1/PD-L1 in combination with chemotherapy or not as first-line treatment for advanced non-small cell lung cancer: A systematic review and network meta-analysis.
Liming Wang, Yifan Yang, +9 authors, Bin Ai.
Thorac Cancer, 2021 Dec 16; 13(3). PMID: 34907661    Free PMC article.
Systematic Review.
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects.
Shengjie Tang, Chao Qin, +7 authors, Haining Zhou.
Cells, 2022 Feb 16; 11(3). PMID: 35159131    Free PMC article.
Review.
Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer.
Zhengyu Yang, Ya Chen, +6 authors, Baohui Han.
Front Immunol, 2022 Mar 04; 13. PMID: 35237263    Free PMC article.
Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis.
Teppei Yamaguchi, Junichi Shimizu, +5 authors, Yutaka Fujiwara.
Thorac Cancer, 2022 Jan 20; 13(5). PMID: 35044093    Free PMC article.
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors.
Nusayba A Bagegni, Haeseong Park, +11 authors, Andrea Wang-Gillam.
Cancer Chemother Pharmacol, 2022 Mar 06; 89(4). PMID: 35247086    Free PMC article.
High Intensity Aerobic exercise training and Immune cell Mobilization in patients with lung cancer (HI AIM)-a randomized controlled trial.
Gitte Holmen Olofsson, Marta Kramer Mikkelsen, +11 authors, Per Thor Straten.
BMC Cancer, 2022 Mar 07; 22(1). PMID: 35247994    Free PMC article.
Multimodal Treatment of Nasopharyngeal Carcinoma in Children, Adolescents and Young Adults-Extended Follow-Up of the NPC-2003-GPOH Study Cohort and Patients of the Interim Cohort.
Tristan Römer, Sabrina Franzen, +27 authors, Udo Kontny.
Cancers (Basel), 2022 Mar 11; 14(5). PMID: 35267570    Free PMC article.
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
Mengling Wu, Qianrui Huang, +4 authors, Yong Xia.
J Hematol Oncol, 2022 Mar 14; 15(1). PMID: 35279217    Free PMC article.
Review.
Adverse events of different PD-1 inhibitors in lung cancer patients: a real-world study.
Xiaowei Zheng, Gang Tao, +5 authors, Ping Huang.
Ann Transl Med, 2022 Mar 15; 10(4). PMID: 35280395    Free PMC article.
TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model.
Ismail M Meraz, Mourad Majidi, +4 authors, Jack A Roth.
Commun Biol, 2022 Feb 26; 5(1). PMID: 35210547    Free PMC article.
Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy.
Jii Bum Lee, Hye Ryun Kim, Sang-Jun Ha.
Immune Netw, 2022 Mar 17; 22(1). PMID: 35291660    Free PMC article.
Review.
Case Report: Opportunities and Challenges of Immunotherapy in Heavily-Treated EGFR-Mutant Advanced Squamous Cell Lung Carcinoma After Progression on EGFR-TKIs and Chemotherapy.
Wei Jin, Xin Wang, Jie Wang, Lin Lin.
Front Oncol, 2022 Mar 18; 12. PMID: 35296008    Free PMC article.
Case Report: Hepatic Sarcoid-Like Reaction Associated With Checkpoint Inhibition in a NSCLC Patient and a Literature Review.
Yuxin Lin, Wei Zhu, Bingchen Wu, Huiyin Lan.
Front Oncol, 2022 Apr 02; 12. PMID: 35359368    Free PMC article.
Anti-PD1 or anti-PD-L1 antibodies alone or in combination with chemotherapy first-line treatment of advanced non-small cell lung cancer.
Xuexia Zhang, Xiaoping Cai, Hao Zheng.
Thorac Cancer, 2022 Feb 25; 13(7). PMID: 35199960    Free PMC article.
Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis.
Birgitte Bjørnhart, Karin Holmskov Hansen, +3 authors, Tine Schytte.
Cancers (Basel), 2022 Apr 13; 14(7). PMID: 35406453    Free PMC article.
Caerin 1 Peptides, the Potential Jack-of-All-Trades for the Multiple Antibiotic-Resistant Bacterial Infection Treatment and Cancer Immunotherapy.
Liyin Xiao, Xiaodan Yang, +10 authors, Xiaosong Liu.
Biomed Res Int, 2022 Apr 22; 2022. PMID: 35445137    Free PMC article.
Review.
The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy.
Cathrin L C Gudd, Lucia A Possamai.
Cancers (Basel), 2022 Apr 24; 14(8). PMID: 35454819    Free PMC article.
Review.
Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial.
Yu Wang, Yuan Kong, +6 authors, Xiao-Jun Huang.
BMC Med, 2022 Apr 28; 20(1). PMID: 35473809    Free PMC article.
Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)-Their Incidence, Management, Multiorgan irAEs, and Rechallenge.
Raju Vaddepally, Rajiv Doddamani, +6 authors, Abhinav B Chandra.
Biomedicines, 2022 Apr 24; 10(4). PMID: 35453540    Free PMC article.
Review.
Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis.
Muhammad Zain Farooq, Sheeba Ba Aqeel, +6 authors, Ankit Mangla.
JAMA Netw Open, 2022 Apr 20; 5(4). PMID: 35438755    Free PMC article.
Systematic Review.
Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies.
Xing Chang, Zi Liu, +4 authors, Yingliang Wu.
RSC Adv, 2019 Jun 07; 9(31). PMID: 35520562    Free PMC article.
Review.
Resistance to chemoimmunotherapy in non-small-cell lung cancer.
Maximilian Johannes Hochmair.
Cancer Drug Resist, 2020 Jul 12; 3(3). PMID: 35582443    Free PMC article.
Review.
A prognostic model using the neutrophil-albumin ratio and PG-SGA to predict overall survival in advanced palliative lung cancer.
Changyan Feng, Huiqing Yu, +3 authors, Shihong Liu.
BMC Palliat Care, 2022 May 19; 21(1). PMID: 35585628    Free PMC article.